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EXECUTIVE
SUMMARY
One problem faced by all companies - start-ups as well as
established ones - is how to finance the research and development necessary to convert their ideas into successful products.
Many companies have recently turned to R&D partnerships for
this financing.
Although R&D partnerships have been used since the
mid-1970s they did not become popular until 1981. Until then,
many investors were wary that the IRS would view such partnerships as elaborate financing/tax sheltering techniques rather
than legitimate projects. But with the large offerings by Storage
Technology Corp. and Trilogy Limited in 1981, backed by
reputable investment bankers, R&D partnerships came of age
and are now acceptable financing vehicles for raising $50,000 or
$50 million, for starting a new company or for funding a mature
one.
The market for R&D partnerships is just starting to be
tapped. In its January 1982 issue, Tax Shelter Insider projected
that the market for R&D partnerships will increase from $160 million in 1981 to $2.25 billion in 1990. In fact, many people believe
that R&D partnerships will soon surpass conventional venture
capital funds in providing seed capital and early-stage financing
to companies conducting R&D.
R&D financing arrangements can be very complex. If you
are an entrepreneur in search of R&D funding and are considering
R&D partnerships, you undoubtedly have many questions and
concerns.
We at Deloitte Haskins & Sells have been advising clients
and assisting them in arranging R&D financing for many years.
As a result of that experience, we have prepared this guidebook
to answer your questions and assist you in understanding and
assessing the potentials of R&D partnerships.
This guidebook is divided into two parts — a main text
and a section of appendices. The main text provides general
information to help you understand the workings of R&D partnerships and to explain how you go about forming one. The section
of appendices spells out the many tax and accounting issues that
you and your advisors must consider if your company is to
achieve its goals.
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The main text contains the following sections:
•

The structure of R&D partnerships. This section explains
how R&D partnerships work and how they provide "up
front" tax benefits to the investors.

•

Designing buy-outs. R&D partnerships are differentiated
by the design of their buy-out arrangements. This section
explains the purpose of the various arrangements, when
each would be appropriate, and why.

•

Should you form an R&D partnership? This form of financing is not for everyone. The guidebook analyzes significant factors that should be considered and compares the
merits of R&D partnerships to debt and equity arrangements. It also discusses the types of companies that are
well suited for an R&D partnership.

•

What investors look for. To successfully market an R&D
partnership, you must understand the investors' perspective. This section examines the features of R&D partnerships that attract investors and the drawbacks of R&D
partnerships as an investment vehicle. It also discusses
the risks that prudent investors should evaluate and the
factors they should consider in analyzing the terms of an
offering.

•

Implementing a program. Implementation starts with a
business plan. Then you must decide on a marketing
strategy, draft the documents, and arrange for ongoing
management of the program.

•

Case studies. A benefit of R&D partnerships is the flexibility you have in designing the arrangements. To illustrate, we present seven different R&D partnerships which
have been organized. These partnerships run the gamut
from seed money to start a new company to a $55 million
public offering.
We also include three extensive appendices:

•

Tax considerations for the partnership. The agreements
must be carefully written to assure that the expected tax
benefits do, in fact, materialize for your investors. We explain in detail all the tax issues you and your advisors
must consider when drafting the documents.

•

Tax considerations for the sponsoring company. The
funds you receive are taxable as revenue, but you can take
steps to avoid using a substantial portion of those funds
to pay income taxes. This appendix also covers (1)the
deductibility of royalty payments, and (2) potential problems you may encounter with the allocation of income
and deductions.

•

Accounting implications. The ability to treat your R&D
arrangement as "off balance sheet financing" will depend
on how the arrangement is structured. This appendix
explains the implications of Statement of Financial
Accounting Standards No. 68, which prescribes the
accounting treatment companies with R&D contracts
should use. This appendix also discusses the accounting
issues related to buy-out transactions.
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1. THE STRUCTURE OF
R&D PARTNERSHIPS
The Limited Partnership
The Sponsoring C o m p a n y
The R&D Contract
The Buy-Out
Variations

SECTION 1
THE STRUCTURE OF
R&D PARTNERSHIPS

R&D partnerships give companies another option for
financing research and development. Instead of using debt provided by lenders, equity provided by stockholders, or cash
provided by internal operations, a company can look to investors
seeking an attractive tax shelter opportunity.
Many well-known companies have used R&D partnerships
to raise money to develop a variety of products:
•

Lear Fan, in an early R&D partnership, raised $25,000,000
to develop a fuel-efficient, turboprop plane.

•

Storage Technology Corporation,
raised $95,000,000 to develop a
puter and an optical disk drive.
largest amount raised to date
through R&D partnerships.

•

Trilogy Limited raised $55,000,000 to start Gene Amdahl's
new company and to develop a high-performance
computer. The first large public offering of its kind, it was
rumored to have sold out in four hours.

•

Syntex Corporation raised $23,500,000 in December 1982
to develop five different medical diagnostic products.

•

Genentech, Inc. raised $55,000,000 in December 1982 to
develop human growth hormone and gamma interferon
products. Six months later, Genentech raised an additional $32,000,000 through a second partnership to
develop a tissue-type plasminogen activator.

in two private offerings,
high-performance comThis $95,000,000 is the
by a single company

The terms of R&D arrangements vary as widely as the products they help create. However, the general concept of R&D
partnerships is very straightforward.
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In a typical R&D partnership arrangement, there are two
parties - a limited partnership and a sponsoring company. The
two parties enter into a contract under which the sponsoring
company will develop the technology for the limited partnership.

The Limited Partnership
R&D arrangements are generally limited partnerships. In
such partnerships the limited partners, like the stockholders of a
corporation, have limited liability. But unlike corporations, partnerships are not taxable entities. Items of partnership income
and loss are allocated to the various partners, who then combine
these items with other items of income and loss on their individual tax returns. Consequently, investors can use their share of
any partnership losses to offset other income they have earned,
reducing their total taxable income and, therefore, their taxes.
In an R&D limited partnership, a general partner (or partners) provides the management. The sponsoring company (or its
subsidiary or other affiliate) or a non-related party serves as the
general partner.
The limited partners are the individual investors. They do
not actively participate in the management of the partnership.
The limited partners, who are generally in the higher income tax
brackets, provide capital to the partnership and benefit from tax
deductions generated by the partnership's expenditures for
research and development.

The Sponsoring Company
The sponsoring company is an entity that wants to fund
an R&D project. It usually possesses the "base technology" to
develop what it anticipates will be a commercially successful
product.
The sponsoring company must make the base technology
available to the partnership. If the company wants to retain access to the technology to use it in products other than the one to
be developed by the partnership, the company can either:
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•

give the partnership a non-exclusive license to use the
technology in the specific project in exchange for a
license fee, or

•

enter into a cross-licensing agreement — the company
gives the partnership a license to use the technology in
the R&D project and the partnership gives the company a
license to use the technology in other applications.

The R&D Contract
The limited partnership and the sponsoring company
enter into a contract under which the company agrees to perform
R&D work to develop a technology for the partnership. The company performs the development work on a best-efforts basis, i.e.,
it does not guarantee any results. The partnership compensates
the company on either a fixed-fee or a cost-plus basis.
The use of an R&D contract between a sponsoring company and a limited partnership gives rise to a current tax deduction for the limited partners. The tax deduction is based on two
tax authorities: Section 174 of the Internal Revenue Code (the
Code) and the case of Snow vs. Commissioner. 1
Sec. 174 allows a taxpayer to deduct R&D costs as paid or
incurred, rather than to capitalize them as part of the product's ultimate cost.
Before 1974, the Internal Revenue Service (IRS) contended that a taxpayer was not entitled to a deduction under
Sec. 174 unless and until the taxpayer was "carrying on" a trade
or business. Further, the IRS felt this criterion was not met
unless the taxpayer was generating revenue or actively offering a
product for sale. In the precedent-setting Snow vs.
Commissioner case, the U.S. Supreme Court ruled that it was
sufficient for the taxpayer to incur the expenses "in connection
with" a trade or business. This broad language supports Sec. 174
deductions in a great variety of R&D arrangements. Most tax
practitioners agree that as long as the partners incur substantial
business risks and have a reasonable expectation of profit, the
arrangements meet the "in connection with" a trade or business
requirement.

1

Edwin A. Snow, 416 US 500 (1974)(33 AFTR2d 74-1251, 74-1 USTC para. 9432).
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Under Sec. 174, partners may be allowed deductions in
the year the partnership makes payments under an R&D contract.
Consequently, when an R&D partnership enters into a contract
with a sponsoring company, the partners' investments are immediately used to prepay all or some of the contract costs. In this
way, the partners are allowed deductions in the year their investments are made, even if the investments are not made until late in
the year.
Neither does the sponsoring company have to spend any
of the funds before year-end. The partners will generally qualify
for the "up front" deductions as long as the contract prepayments are not construed as deposits and sufficient business
reasons exist for prepaying the contract costs.
For a limited partner in the highest income tax bracket,
this tax deduction immediately reduces the amount at risk and
nearly doubles the potential rate of return. In contrast, investors
who purchase stock in a company receive no tax deductions.
Consequently, investors who are looking for a specified rate of
return should be satisfied with lower cash returns as limited partners in an R&D arrangement than as shareholders in a corporation.
(NOTE: Throughout this guidebook we mention various tax
aspects of R&D partnerships because these aspects are important in understanding why R&D partnerships are structured as
they are. However, the taxation of R&D partnerships is a complex
subject. We devote Appendix I to a detailed explanation of the
many tax issues.)

The Buy-Out
The limited partnership owns the rights to the results of
the R&D project. When the R&D work is completed, the sponsoring company usually exercises its option to acquire these rights
from the partnership through three basic types of arrangements
— royalty, equity, and joint venture.
Royalty Partnerships
In the typical royalty partnership arrangement, the
company exercises an option to either: (1) purchase the
technology, (2) purchase the partnership interests of the limited
partners, or (3) acquire an exclusive license to use the technology
to manufacture and market the resulting product. In exchange,
the company pays the partners or the partnership royalties based
upon sales of products using the technology.
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Royalty rates frequently range from 6% to 10% of gross
sales. The rate may remain constant or decline as the sales
volume reaches certain levels. There may also be an upper limit,
or cap, on cumulative royalties paid; a specified time period that
royalties must be paid; or minimum and/or maximum limits on annual royalties paid.
The company may have an option to pay the partnership a
lump-sum cash amount instead of royalties, either at the time the
purchase option is exercised or at later dates. In some instances,
if the company chooses a lump-sum payment, the partnership
can opt for that payment in cash, company stock, or a combination of both.

Figure 1-1: Royalty Partnerships

Investors

R & D Funds
Developed Technology
R&D
Partnership

Sale of Technology

Sponsoring
Company

Royalties

Equity Partnerships
In the typical equity partnership arrangement, the partnership and the company agree to form a new corporation after
the technology is developed. The partnership interests can, at the
partners' option, be converted in a tax-free transaction to equity
in the new corporation, based upon a formula set when the R&D
contract was negotiated. In this way, the partner/investor winds
up with an equity interest in the continuing entity.
Pure equity partnerships are designed to launch new
companies. Such partnerships usually provide seed capital or
first-round financing for new ventures. Closely resembling a venture-capital type of investment, an equity partnership provides
the investor with the added advantage of current tax deductions.
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Figure 1-2: Equity Partnerships
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The early equity R&D partnerships were established with
the entrepreneur as general partner and the tax-oriented investors as limited partners.
In recent versions, the entrepreneur forms a corporation
and obtains traditional venture capital investors. The entrepreneur and key employees receive common stock and/or options,
while the investors receive a series of preferred stock. Funds
provided by the venture capitalists are used for non-R&D expenditures.
A limited partnership is then organized with the corporation as the general partner and tax-oriented investors as the
limited partners. The corporation contracts with the R&D partnership to perform the development work, using funds invested by
the limited partners. The limited partners are usually allocated
99% of the contract costs as Sec. 174 deductions.
Partnership income is allocated on a negotiated basis. In
actual practice, the partnership probably will never realize income. The profit allocation's real purpose is to define the relative
interests of the parties so that stock can later be proportionately
distributed.
16

When the technology is developed, the partners exchange their interests in the partnership and the shareholders of
the corporation exchange their shares of stock for the stock of a
successor corporation in a tax-free transaction. The successor
company manufactures and markets the new product.
This equity partnership arrangement works well when
(1) significant funds for non-R&D expenditures are needed, and
(2) some investors do not need current tax deductions but are
willing to participate side by side with tax-advantaged investors.
Joint Ventures
In a joint venture arrangement, the company and the
partnership form a joint venture to manufacture and market the
product after the technology has been developed. At some point
the company buys out the partnership's interest in the joint venture, or vice-versa, pursuant to cross-purchase options in the
joint venture agreement.

Figure 1-3: Joint Ventures
Investors

R & D Funds

R&D
Partnership

Developed Technology

Joint
Venture
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Sponsoring
Company

From the company's perspective, the formation of the
joint venture is an interim step which allows the company to start
production and marketing. During this period, profits (which may
not be significant at the initial sales levels) are split between the
company and the partnership. Since these profits are normally
less than royalty payments, the company has more funds to use
in operations during this period. After a period of time, the company exercises an option to purchase the partnership interests.
In practice, the joint venture is most often used only as a
vehicle to meet several criteria for advantageous tax treatment
for the partners. The tax treatments available to the partnership
are an important consideration in structuring an R&D partnership
arrangement, and are a primary factor in determining what type of
buy-out arrangement should be used. Section 2 discusses at
length the implications of the various arrangements.

Variations
As R&D arrangements proliferate, new features are constantly being devised to suit the particular circumstances of each
situation. Each arrangement reflects trade-offs among the risks,
the rewards, and the needs of the investors and the sponsoring
company. Some recent popular techniques include:
Hybrid Arrangements
In an increasingly popular hybrid of royalty and equity
arrangements, the company issues warrants entitling the partnership to purchase stock. Consequently, the partnership receives
both royalties and a right to acquire equity in the sponsoring
company.
The equity portions of the arrangement are added when
the tax advantages are not sufficient to entice investors, or when
the investors will participate in the partnership primarily to be
able to acquire that equity in the sponsoring company.
With its R&D offering in June 1983, Cetus, Inc. issued
warrants to purchase stock at $23 per share, exercisable for four
years. At the time of issuance, Cetus common stock was trading
at $20 per share. The investors have two potential ways of receiving a return on the investment — through the payback on the
R&D partnership itself and/or through increases in the market
value of the sponsoring company's stock. Consequently, their
risk is reduced. The Cetus arrangement reflects the current trend
of including warrants in publicly-syndicated offerings to make
those offerings more marketable.
18

Blind Pools
Brokerage houses and R&D and venture capital funding
groups have recently begun sponsoring blind pool R&D partnerships. Many people believe blind pools will soon be the largest
vehicles for marketing R&D partnerships.
Investors invest in blind pools rather than in specific
ventures. The sponsors then use the pooled funds to invest in a
variety of ventures in a manner similar to venture capital funds.
Because a new group of investors need not be formed for
each new venture, R&D should be easier and less expensive to
form and to market. More important, however, investors have the
added benefit of spreading their risk among several projects.
Non-tax-oriented Investors
Investors often are interested in certain R&D arrangements, but have no need for current tax deductions. A partnership may be established with two classes of limited partners. Taxoriented investors are allocated all of the R&D deductions, while
non-tax-oriented investors purchase limited-partnership interests
at a reduced price (generally about 20% less) in lieu of any tax
benefits. The Alpha Partners case in Section 6 is an example of
such a partnership.
Tax Advantaged Start-up Partnerships
A start-up company can be established as a partnership,
where the founder serves as the general partner and venture
capitalists purchase limited partnership units. The partnership
performs the R&D and begins to market the product. Just before
the partnership begins to show a profit, the partners can opt to incorporate and convert the partnership units, tax-free, into shares
of the new corporation.
These types of partnerships are not actually R&D partnerships; however, the start-up partnership (like the equity R&D
partnership) provides equity investors with some tax benefits.
Start-up partnerships have actually been used for many decades,
but they are now experiencing renewed popularity, in part because of the popularity of R&D equity partnerships.

19

In a start-up partnership, the expenses incurred by the
partnership do not flow through to the partners until those expenditures are actually made. Consequently, the tax benefits are not
realized by the partners as quickly as the benefits of an R&D equity partnership. However, the start-up partnerships are much
simpler and cheaper to organize, and are not subject to some of
the tax issues surrounding R&D partnerships.
In another variation of this, many emerging companies
today are establishing partnerships or joint ventures to which the
companies contribute a developed product. The venture is formed
to finance the costs of marketing that product and the costs to
develop the next generation of products or an entirely different
product. Because the venture is carrying on a trade or business
from the onset, the partners/investors are allowed to deduct the
marketing costs related to the existing product as well as premarket and development costs for successor ones. In effect,
investors make second or third round financing investments
through a tax-advantaged vehicle.
Corporate R&D Arrangements
Many companies are beginning to create R&D joint
ventures with other companies in order to pool their resources
and to share the research results. For example, Microelectronics
and Computer Technology Corp. was formed in 1982 by fourteen
sponsoring companies, including Honeywell, Digital Equipment,
Motorola, National Semiconductor, and NCR. With an anticipated
annual budget of $50-100 million, it represents a cooperative effort to develop a broad base of fundamental technologies for use
by the member companies. The expectation is that each sponsor
will then build on the basic technology and continue to compete
with each other with products and services of individual conception and design. As another example, Hewlett Packard Co. and
Genentech Inc. agreed in July 1983 to begin a joint venture to develop instruments for the biotechnology industry.
While these do not represent R&D partnerships in the
usual sense, they are R&D partnerships nonetheless, representing a new trend in the way that American companies are funding
R&D.
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2. DESIGNING BUY OUTS
Section 1 2 3 5 — Sale of Patents
Sections 1221-23 and Section 1231
Other Techniques for Capital Gains
Treatment
Executing the Buy-Out

SECTION 2

The ideal tax shelter permits income to be treated as longterm capital gains. Such gains are taxed at a maximum rate of
20%, as opposed to a maximum rate of 50% on ordinary income.
Most R&D partnership buy-out arrangements are designed with
this tax consideration in mind.
For investors, the possibility of receiving capital gains
treatment on income from R&D partnerships is a major attraction.
It is also a significant factor in increasing the investors' potential
rate of return. R&D partnerships can achieve capital gains treatment on buy-out arrangements by making use of various Code
sections.

Section 1235 - Sale of Patents
Under Sec. 1235 the sale by a qualified holder of all substantial rights to a patent or patentable technology will be taxed
as long-term capital gains, regardless of the holding period.
Sec. 1235 has two advantages over other available Code
sections. The partnership is not required to establish the twelvemonth holding period that is normally required for long-term
capital gains status; so it can sell the technology as soon as the
research contract is completed. Additionally, property sold under
Sec. 1235 is automatically considered a capital asset, avoiding
the issue of whether the technology is inventory (see discussion
below).
However, the use of Sec. 1235 is limited, primarily
because of the following:
•

The requirements to qualify the partners as "holders" are
elaborate and, in some cases, the base technology
cannot be transferred so that the limited partners qualify.
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•

Sec. 1235 only applies to patentable technology or to that
portion of a technology that is patentable. For example,
with a computer system that includes both patentable
hardware and nonpatentable software, Sec. 1235 would
not apply to the software portion.

Sections 1221-23 and Section 1231
In those situations where Sec. 1235 does not apply, the
partners may be able to receive long-term capital gains treatment
on the sale of the technology, relying on Secs. 1221-23 (capital
assets) or Sec. 1231 (property used in a trade or business).
Under these Code sections, the invention need not be
patentable. To qualify, however, the technology must be viewed
by the IRS as a capital asset. That is, the technology cannot be
viewed as inventory — property held primarily for sale to customers in the ordinary course of the partnership's trade or
business.
Additionally, the technology must be held by the partnership for at least twelve months from the time the technology was
reduced to practice. Consequently, many technology purchase
options specify that such options are not exercisable until a certain period after the technology is reduced to practice. In the
meantime, the technology is used either by a joint venture of the
partnership and the sponsoring company, or by the sponsoring
company under a non-exclusive short-term license from the
partnership. 2

Other Techniques for Capital Gains
Treatment
Tax complications sometimes arise when technology is
acquired with reliance on Secs. 1221-23 and 1231 for capital
gains tax treatment. Some of these issues (such as whether the
asset constitutes property, whether a complete sale has
2

If the technology is subject to rapid obsolescence, this strategy of licensing the
technology may not be practical. In such a case, the greatest revenue from the
technology is likely to be earned during the license period, and all this income
would be ordinary income. Only a small amount might ultimately be eligible for
long-term capital gains treatment. In contrast, the likelihood of capital gains
would be considerably greater in a Sec. 1235 arrangement. Therefore, some
practitioners advise that, in evaluating actual yield, the investor should assume
that the return in non-Sec. 1235 arrangements will be ordinary income and make a
judgment on the feasibility of the investment accordingly.
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occurred or whether the tax benefit rule applies) may be avoided
by having the partners sell their partnership interests rather than
the technology. If the partnership interest has been held for one
year or more, its sale qualifies for capital gains treatment. (Some
of the gain will be treated as ordinary income if the partnership
assets included receivables unrecognized for tax purposes or if
the assets included inventory. The partnership may still need to
hold the technology for a year to qualify the technology as a
capital asset and avoid taxation of that portion of the gain as
ordinary income. See Appendix I.)
Still other techniques to acquire the technology include
incorporation of the partnership or a tax-free merger of the partnership into the sponsoring company (where the stock received
can later be sold as a capital asset). Either of these techniques
can result in the partners receiving capital gains treatment, but
because they are not unique to R&D partnerships, the tax issues
and requirements will not be addressed here.

Executing the Buy-Out
The three basic types of buy-out arrangements are
designed to take advantage of the Code sections allowing for
capital gains treatment.
Most royalty partnerships are structured to attempt to
qualify for capital gains treatment under Sec. 1235, purchase of
the partnership interest, and Secs. 1221-23 and Sec. 1231 as well.
The partnership usually provides the company with a review period/option period of twelve months or more prior to the time the
company has the right to purchase the technology.
Often, a joint venture is used solely for the purpose of
creating that holding period. After the development work is completed, the partnership and the sponsoring company form a joint
venture. The partnership gives the joint venture a short-term license to use the technology for at least twelve months after the
technology is reduced to practice. At the end of that period, the
company has an option to buy the technology or the partnership
interest by paying royalties or by making a lump-sum payment.
For example, see the Diversified Technology arrangement described in Section 6.
In addition to meeting the partnership's holding period
requirements, the joint venture establishes that the technology
was not developed solely for sale but for the primary purpose of
applying the technology to the manufacture of products for sale.
Consequently, the partnership avoids the issue of whether the
technology constitutes inventory.
25

You must be careful that the purchase option and the joint
venture agreement are not too similar and that the joint venture
agreement is not more detrimental to the sponsoring company
than the purchase option. Otherwise, the IRS may ignore the joint
venture arrangement and assert that the purchase option was in
substance exercised at the time the joint venture was set up. This
assertion would destroy your twelve-month holding period. To
avoid this problem, many purchase options require a substantial
payment at the time the option is exercised. The payment may be
applied against future royalties, but the need for the company to
make that payment in advance is an indication that the purchase
option is more detrimental to the company than the joint venture
arrangement.
In another type of joint venture arrangement, the
company and the limited partnership form a joint venture to both
develop and commercially exploit a technology or product. The
partnership contributes cash for the initial funding of the joint
venture, while the company contributes management and a license to existing technology. The joint venture then contracts
with the company to perform the development work. After development is completed, the joint venture (rather than the company)
will attempt to exploit the new product. It will contract with the
company to manufacture the product, and it will sell the product
either directly or through the company. The company usually has
the option to buy out the limited partnership's interest in the joint
venture after a specified period. Because the joint venture may be
viewed as carrying on a trade or business, this type of arrangement may allow the joint venture (and, consequently, the limited
partner) to deduct certain non-R&D expenditures. Any income
generated by the joint venture will be taxed as ordinary income,
but the gain from the sale of the joint venture or limited
partnership interest may be taxed as long-term capital gains (except for that portion representing substantially appreciated inventory — see Appendix I).
With equity arrangements, the expectation is that if the
development is successful the partnership interests will be exchanged into shares of the sponsor company or a new company.
In these and other buy-outs for stock, the treatment of the transaction as nontaxable is critical because investors may not have
the cash with which to pay the related taxes. In a merger of a
company and a partnership into a new company, additional contributions from corporate shareholders may be necessary to
qualify the transaction as tax-free. When the stockholders sell
their shares of stock, they may recognize capital gains.
When forming an R&D partnership, you must decide what
Code sections will apply to your situation, so that the right arrangement can be selected, so that the buy-out will take place at
the appropriate time, and so that nothing is done at formation
that would preclude the partnership from receiving capital gains
treatment.
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SECTION 3
SHOULD YOU FORM AN
R&D PARTNERSHIP?
R&D partnerships are now an acceptable source of
financing for companies in every stage of development and of
every size. But they may not be the best source for everyone. If
you are seeking R&D funding, you should carefully compare the
merits of R&D partnerships to those of debt and equity
arrangements.

Advantages
R&D partnership financing provides many attractions to
the sponsoring company. The major benefits include:
Less Dilution
When R&D royalty partnerships came into vogue in the
late 1970s, an often-stated reason for companies to use them was
to avoid the dilution to current shareholders which would occur if
additional stock were sold to fund the R&D. For example, Gene
Amdahl was said to have selected an R&D partnership for his new
company, Trilogy Limited, so that his interest in Trilogy would not
suffer the dilution his interest in Amdahl Corporation had
suffered.
The dilution impact can be significant. A Silicon Valley
company that recently sought first-round financing found that
out quickly.
The founders of this company had contributed $125,000
and had done preliminary R&D on their new product. They
decided that an additional $3.5 million would be needed in the
next 12-15 months for research and development expenditures,
and another $1 million would subsequently be needed for start-up
manufacturing and initial marketing. Additionally, the company
wanted to establish a 35% equity participation plan for its management team. The company negotiated financing proposals
with two different venture capital groups as follows:
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Option 1
Founders (original investment)
Management stock purchase plan (notes)
Venture capital investors
Total

Investment

Equity

$ 125,000
350,000
3,500,000
$3,975,000

5%
35%
60%
100%

$ 125,000
135,000
3,500,000
1,500,000
$5,260,000

24%
35%
7%
34%
100%

Option 2
Founders (original investment)
Management stock purchase plan (notes)
R&D royalty partnership*
Venture capital investors
Total

* The R&D partnership called for royalties with a cap of 3.5 times
the amount invested plus warrants to purchase a 7% interest
in the company.

In Option 1 - an equity venture capital placement - only
$3.5 million could be raised, and the company had to give up a
60% interest in the company. It could not raise the entire $5 million and still retain 35% of the equity for its management team.
Therefore, it would have to seek second-round financing before
proving the product's marketability and the company's ability to
profitably produce it.
In Option 2 - a combination of equity venture capital and
an R&D partnership - the company was able to raise $5,000,000.
With this option, the next round of financing would not have to
occur until the company had assessed its marketing and production risks. At the same time, the founders and management
retained much greater ownership. They received 43% more capital, yet retained a 59% ownership position - 48% more
ownership than under the first option. Of course, there may be a
substantial cost to the company later. If the project is successful,
the company will have to pay up to $12 million in royalties.
With equity and joint venture arrangements, dilution obviously cannot be avoided, since these arrangements are designed to convert partnership interests into equity interests in
your company. Dilution occurs eventually, but will still not be as
significant as the dilution in a pure equity placement. While the
conventional venture capital investor may want to end up with
45% to 65% of a company, the equity partnership investor will
settle for 30% to 50% in the same situation. Because the latter
receives up-front tax benefits, the after-tax return on investment
is comparable.
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Even with royalty arrangements, the avoidance of dilution
may be illusory. If royalties are to be paid out at a high rate, you
may find it difficult to face the commitment on a long-term basis
and be forced to buy out the partnership interests. If you have no
cash for the buy-out, you may have to give the partners an equity
interest, resulting in the very dilution you initially set out to avoid.
The ultimate dilution, however, would still be less than if you had
initially raised equity capital to finance your company.
So even if you can't avoid dilution entirely, you can expect
less dilution. Additionally, if some or all of your R&D effort can be
accomplished through the R&D partnership, subsequent venture
capital financing will require even less loss of equity. Once you
have completed the development of your product or have a
prototype in place, your risks will have been reduced, so that the
venture capitalist providing second-round financing will settle for
a smaller share of your company.
Transfer of Risk
In many cases, research and development projects represent substantial risk to a company. A significant benefit of R&D
partnership funding is that the risk is borne by the limited partners rather than the company. R&D partnerships allow you to insulate your business from the risk of a new project failing. There
is no cost or other risk of loss to you if the product cannot be developed. You pay only for successful development and sale of the
product.
In reality, however, you may find it very difficult to completely walk away from an unsuccessful project. You will create ill
will in the investor/partners and in the general investment community that may cause long-term problems for your company.
The value of your company's stock may be adversely affected because of the company's association with a well-publicized unsuccessful program. And if stock analysts perceive the R&D program
to be critical to your company, the program's failure could also affect the stock value.
Retention of Control
With less dilution, you retain greater control of your company and, consequently, control over the direction of the
product's development. However, the general partner
(independent or not) does have a fiduciary responsibility to
monitor the progress of the R&D project and to insure that you
are adhering to contract specifications.
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Reacquisition Rights
If the R&D project is successful, R&D partnership
arrangements allow you to reacquire all rights to the product.
Accounting Treatment
If the R&D partnership bears the risk of loss if the project
is unsuccessful, then the R&D arrangement will have a favorable
impact on your company's financial statements during the years
of the project. Your R&D expenditures are offset by revenues
received from R&D contracts. In effect, your company's earnings
are not affected by your R&D efforts. To illustrate, if you were to
undertake a $1,000,000 R&D project with either (1) a costplus-10% R&D contract, (2) borrowings at 15% interest, or (3)
equity, your earnings would be affected as follows:

Contract revenue
R&D expense
Interest expense
Pre-tax effect
Income taxes (at 50%)
R&D tax credit*
After-tax effect
on earnings

R&D
Partnership
$1,100,000
(1,000,000)

$

Debt
Financing

Equity
Financing

$(1,000,000)
(150,000)
(1,150,000)
100,000
(50,000)
575,000
100,000

$(1,000,000)

$ (475,000)

$ (400,000)

50,000

(1,000,000)
500,000
100,000

* Assumes that 80% of expenditures qualify.

With R&D partnerships, should you exercise your option
to reacquire the rights to the technology, you purchase those
rights with royalties on future revenue or with lump-sum payments of cash and/or stock. This makes it possible for you to
match the expense of the technology development (royalty expense or amortization of product rights) with revenues received
from products using the technology. This impact on your financial statements can have a positive effect in subsequent equity
offerings or attempts to acquire additional debt.
Properly structured, an R&D partnership also provides
"off balance sheet financing," i.e., you do not show the funds
from the partnership as debt on your financial statements. Consequently, your debt-equity ratio, a ratio that lenders evaluate
critically, is improved. A company funding its R&D with a limited
partnership is likely to be extended more credit than a company
funding its R&D with debt, assuming all other factors are the
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same. The debt-funded company may actually be healthier financially, since its debt burden is probably not as substantial as the
other company's royalty commitment. However, its higher debtequity ratio can result in it receiving less credit.
The accounting treatment of R&D arrangements is dependent on the way the arrangements are structured. The accounting
issues are discussed in detail in Appendix III.
Better Cash Flow
The R&D partnership approach helps you avoid the initial
debt-service requirements. Debt may produce much earlier negative cash flow since the typical loan requires that, shortly after
getting the loan, you begin repaying it in periodic installments.
Royalty payments for R&D partnership funds commence only
after the research has been completed, the technology has been
acquired, and sales of the product have commenced.
It also allows you to conserve your debt capacity, which
can be used for other purposes.

Disadvantages
There are also some very significant disadvantages to
R&D partnerships.
High Cost of Capital
If successful, the cost of R&D funds is very expensive to
the sponsoring company. Because of the risks inherent in R&D
projects, the investors' return must be greater than the return offered by less risky ventures. The cost generally ranges from
25%-45% on an annualized after-tax basis, plus the benefit of
R&D tax credits is lost. Generally, R&D partnerships will be less
expensive than equity, but more costly than debt.
The following table compares the cost of funding a
$1,000,000 R&D project with (1) a 15% loan, and (2) an R&D partnership designed to provide the investors with a 50% pre-tax rate
of return on their net investment.
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Length of Project
2 Years
4 Years
Debt Funding
Loan proceeds
Interest expense
Tax benefit
R&D expense
Tax benefit
R&D tax credit*
Loan repayment at
end of project
Earnings on excess
funds**
Net project cost

Partnership Funding
R&D contract proceeds
Tax expense
R&D expense
Tax benefit
Royalty payments
Tax benefit
Net project cost

6 Years

$1,000,000
(300,000)
150,000
(1,000,000)
500,000
100,000

$1,000,000
(600,000)
300,000
(1,000,000)
500,000
100,000

$1,000,000
(900,000)
450,000
(1,000,000)
500,000
100,000

(1,000,000)

(1,000,000)

(1,000,000)

26,300
$ 523,700

71,300
$ 628,700

105,600
$ 744,400

$1,000,000
(500,000)
(1,000,000)
500,000
(1,125,000)
562,500
$ 562,500

$1,000,000
(500,000)
(1,000,000)
500,000
(2,531,250)
1,265,625
$1,265,625

$1,000,000
(500,000)
(1,000,000)
500,000
(5,695,310)
2,847,655
$2,847,655

* The tax credit was calculated with the assumption that 80% of
the expenditures will qualify for the credit.
** At the end of the first year, the company will actually have
$525,000 of positive cash flow. That amount is assumed to be
invested at 10% and used to pay the interest costs of
subsequent years.

For a project requiring two years from the beginning until
the company pays off the loan or buys out the partnership, the
cost difference between the debt-funded project and the partnership-funded project is not significant. However, the longer the
project, the greater the difference in cost.
High Royalty Provisions
If royalty provisions are too high, they can eat into profit
margins. Gross margins on products subject to royalties must be
at least 40-50%; otherwise, margins after royalty payments may
be too low to offer any incentive to market the products. Consequently, such partnerships may not be appropriate for your
company's product.
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Restricted Use
The funds from R&D partnerships are restricted for R&D
expenses (as defined in the R&D contract) related to a specific
project. The project may require other funding, i.e., funds may be
required for market surveys, production equipment, etc. Although these expenditures may be funded out of profits realized
on the R&D contract, you may still need to secure equity or debt
financing to fulfill all your needs.
Expensive to Establish
Creating R&D partnerships is expensive and time-consuming. Management must devote much time to the effort, and
fees may have to be paid to underwriters, attorneys, accountants,
and the general partner. After the partnership is formed, partnership records must be maintained and tax returns must be filed.
Potential Impact on Subsequent Public Offering
You may be contemplating a future public stock offering
for your company. If so, you must consider whether the royalties
to be paid are so high that earnings during the years before the offering will be too low for your stock to command the appropriate
price. If at the time of your offering you have significant royalty
commitments, the public offering valuation will be adversely affected. Even if you can get out from under the commitments
created by the R&D partnership before the offering, analysts understand that a lump-sum cash or stock buy-out will require you
to amortize the capitalized cost. That amortization will reduce future financial-statement earnings, whereas a company that has
funded R&D with debt or equity has already recognized its R&D
costs. This factor can affect the public offering valuation
substantially.

Are You a Potential Candidate for R&D
Partnership Funding?
R&D partnership financing can be appropriate for companies of all sizes and in varying stages of maturity. A start-up
company can be an appropriate candidate, especially if substantial R&D is required to develop that company's product. Venture
capital equity is usually obtained to pay non-R&D expenses and
to satisfy capital asset requirements.

35

Emerging companies that already have one or two existing products in the marketplace may also be good candidates.
Partnership funds can be used to develop new products while the
company's capital may be conserved to finance current growth.
Established companies, including Fortune 500 companies, have also begun to finance new products recently through
R&D partnerships. The funds are frequently used to develop products which, although related, are ancillary to the companies'
primary business.
A key consideration in determining whether an R&D
partnership is appropriate is the size of the potential market for
the products to be developed relative to the amount of development funds required. The market must be big enough to provide
investors with an attractive rate of return from royalties on sales
of the products.
It is also important that you have access to other capital
to finance expenditures not related to R&D. R&D partnership
financing is not, over the long-term, a substitute for debt and
equity. Instead, it supplements these conventional capital
sources. You may need to seek an appropriate mix of (1) debt for
working capital and fixed asset acquisitions, (2) equity to support
debt and to acquire fixed assets, and (3) R&D partnership funds to
finance R&D projects.
Before undertaking an R&D partnership arrangement, you
should first determine the related cost of capital and compare
that cost to alternatives like debt and new equity. You can refer to
R&D offerings made by other companies or get assistance from
investment bankers, R&D partnership service firms, or your accountants to determine the probable financing terms. You can
then estimate the capital costs of partnership financing and compare these costs with other available financing options. Weighing
the costs with the other advantages and disadvantages we discussed in this section, you can then decide whether it is the
appropriate course for you.

36

4. WHAT INVESTORS
LOOK FOR
What Attracts Investors
The Drawbacks
A s s e s s i n g the Risks
Analyzing the Offering
The Impact of TEFRA

SECTION A
WHAT INVESTORS
LOOK FOR
R&D partnerships have attracted the interest of many
investors. These partnerships have some of the same allure as
venture capital investments, as most of them offer the opportunity to participate in the development of glamorous technology
and to make substantial financial profits. Additionally, R&D
partnerships often do not require as large an investment to participate — some of the new blind pools require a minimum investment of only $5,000.
Before you create an R&D partnership, you should be
aware of what investors are seeking in these arrangements and of
how these investors evaluate their potential return.

What Attracts Investors
Investors may find R&D partnerships attractive for many
reasons:
Current Tax Shelter
They can deduct a substantial portion of their investment
against their ordinary income. In non-leveraged deals, the deduction can be as much as 85% to 95% of the investment. This
reduces the after-tax dollars which the investors have at risk and,
for those in the highest tax brackets, also nearly doubles the
potential return.
Large Return
To be marketable, most R&D partnership investments
should pay a 45% to 55% after-tax rate of return on the investors'
net investment. This is generally a yield of at least four times the
investors' cash investment (the so-called "cash-on-cash" return)
and could be even greater depending on how long it takes the
investor to get that return.
Payout at Capital Gains Rates
Investors will also be attracted to arrangements that
enable them to recognize income from their investment at longterm capital gains rates.
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Potential Equity Position
Many R&D partnerships provide investors with the option
to receive stock in the company in exchange for the rights to the
technology. Therefore, they can make an equity investment with
the added advantage of up-front tax benefits.
Earlier Payout
With royalty R&D partnerships, investors begin receiving
cash returns as soon as sales of the product commence, whether
the company is generating profits or not. Consequently, these investors are paid back much sooner than those investors dependent on the company's profitability.
No Dependence on Profits
With royalty arrangements, investors are somewhat insulated from the uncertainty of the long-term profitability of a company. Because royalties are based on sales rather than profits, investors need not be as concerned about whether the company
will ultimately be profitable. Investors will, however, have some
lingering concern because if the company is not profitable it may
not exist long enough to meet its royalty commitments.

The Drawbacks
The potential financial rewards for R&D partnerships are
very high because of the substantial risks involved. Most partnerships have investor suitability standards which require investors
to meet certain net worth or annual income levels at the time the
investment is made.
As an investment vehicle, R&D partnerships also have
some other disadvantages.
No Liquidity
The partnership units have no public market and are
generally restricted as to transfer (i.e., consent of the general
partner).
Possible Financing Shortfall
The costs to develop a new product are never certain, and
you face the possibility that additional funding may be required.
Investors may need to contribute more money. Alternatively, new
investors may need to be found, which could cause substantial
dilution to the existing limited partners.
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No Control over Business Decisions
Limited partners have little or no control over business
decisions. Quite often, the general partner is the sponsoring
company, although independent general partners are appearing
with more frequency. While independent general partners may
avoid conflict-of-interest problems, the limited partner investors
still have no voice in any decisions.
Close IRS Scrutiny
The tax laws affecting R&D partnerships are complex and,
in many cases, vague. The IRS, in its quest to crack down on
abusive tax shelters, is scrutinizing R&D partnership arrangements carefully. If the investors' tax benefits are disallowed, the
investors' overall rate of return may be insufficient for the risks
they take.

Assessing the Risks
The tax shelter aspects of R&D partnership programs are
very alluring to investors, and many promoters emphasize these
aspects. However, prudent investors must assess the probability
of receiving long-term financial returns on their investment. Just
as a venture capitalist analyzes the risks before investing in a
new business, your investors should analyze the economic
realities and basic business risks inherent in your R&D partnership arrangement.
The technology risk — the risk that the proposed R&D
project will not be successfully completed — is the first risk that
must be evaluated. R&D partnerships can run the gamut from
high-risk, pure research deals to less risky, so-called "Big D"
(mostly development) partnerships. Will the R&D effort require
state-of-the-art research or will it be primarily development of
existing technology? Does the sponsoring company have the
technical ability to successfully complete the project? Can the
project be completed with the funds provided by the R&D
partnership?
In evaluating R&D partnership investments, a prudent
investor will not focus exclusively on the technology risk. Some
say that the technology risk accounts for no more than 20% of
the total risk; if the project is successful, then investors are
exposed to a potpourri of other risks.
•

Management risk. The investors' long-term financial
return will be dependent on future sales to generate royalties or to generate income. Consequently, the company's
management must be capable of running successful
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production and marketing operations. Does the management team have sufficient skills to manage what could be
a fairly complex organization?
•

Financing risk. Once the development is completed, the
company will require additional capital to finance the
production and marketing of the developed product. Will
the company be able to obtain this additional capital?

•

Manufacturing risk. Researchers sometimes tend to do
their work to create a prototype that performs according
to planned specifications, but with little consideration
given to building the prototype that can be mass produced efficiently. This can be especially true with high
technology development. Can this magnificent product
actually be manufactured? Will manufacturing costs be
so high that the product is essentially unsalable? Are
critical components of the product in short supply? Are
costs to manufacture the contemplated product changing
so rapidly that the manufacturing risk is unacceptable?

•

Marketing risk. For investors to realize any substantial
return on their investment, the product must be successfully marketed. Does the overall product concept make
sense? Is there a need for the product? Is there a large
potential market? Will it still be there when the product is
ready? How realistic is the anticipated market share?
What is the competitive environment?

•

High technology risks. Most R&D partnerships today are
formed to develop high technology products. If investors
can satisfy themselves as to all of the above risks, they
must also evaluate the vigorous competition, rapid obsolescence and dynamic markets which generally characterize the high technology industry and its products.

If investors cannot be satisfied that the sponsoring company has a high probability of overcoming these risks, then no
matter how high the potential return, they will not invest.

Analyzing the Offering
Once an investor is satisfied with the feasibility of the
venture, the investor must analyze the terms of the offering. The
potential rate of return must be adequate given all the risks
associated with the partnership. Many specialists feel that,
considering the risks, a 45% to 55% annual rate of return is appropriate for the R&D partnership investor. Depending on the particular circumstances, higher or lower rates may be appropriate.
42

A company can be saddled with royalty rates ranging from
2% to 30% of sales, with maximum royalties ("a cap") ranging
from three times the initial investment to unlimited royalty payouts. In analyzing the pricing of the investment, investors should
evaluate the probability that the company will attain its revenue
projections. For example, Genentech's prospectus for its first
R&D partnership contains a table showing the potential financial
return to limited partners. The table is based on projected
revenues of more than $8.1 billion from the developed product
over fourteen and one-half years.
How likely is it that the company will reach these sales
levels? Investors should determine what their return would be if
projected sales levels are not reached or if development is
delayed.
The investor should also make certain the arrangements
are structured by experienced experts in such a way that the
limited partners' interests will be protected and the potential tax
benefits will be retained.
A vast array of R&D partnerships of the "suede shoe"
variety has appeared. Many boast multiple write-offs in excess of
five times the cash investment. Investors should view such
partnerships with a high degree of skepticism, since the partnerships probably will be considered "abusive tax shelters" by the
IRS. Without due diligence performed by the research group of a
major investment banking firm or a competent professional
general partner, the risks associated with R&D partnerships
increase dramatically.
Because R&D partnership financing is a relatively new
investment vehicle, there is little information available on the
successes of past R&D offerings. One R&D partnership - an arrangement with Metricon (a private Silicon Valley laser manufacturer) - received significant publicity when it was bought out
within 18 months by Johnson & Johnson for reportedly five times
the partnership's initial investment of $750,000. On the other
hand, the first DeLorean limited partnership appeared to be doing
quite well when each of the $100,000 partnership units was converted into 2,857 shares of $8.00 cumulative dividend convertible
preferred stock (which the company elected to issue in lieu of
cash payments of $285,700 per unit); yet DeLorean Motor Company is now in receivership.
For most of the R&D partnerships that have been formed,
the results will not be known for some time. Clearly, they are
high-risk investments. But if investors find one that appears to
have a reasonable chance of success and is professionally
structured, an R&D partnership can be an attractive taxadvantaged investment opportunity.
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The Impact of TEFRA
The Tax Equity and Fiscal Responsibility Act of 1982
(TEFRA) implemented several laws which reduced the tax
benefits associated with various tax shelters. Beginning in 1983,
investors have to include deductions for R&D expenditures
as tax preference items subject to the alternative minimum tax.
The alternative minimum tax is equal to 20% of
alternative minimum taxable income (generally, adjusted gross
income plus items of tax preference) in excess of exemption
amounts. Taxpayers will be subject to the alternative minimum
tax to the extent that it exceeds their regular tax.
The alternative minimum tax is complex, and the impact
of this new provision will depend on each individual's tax
situation, including the amount of income subject to regular tax
and the extent of other items of tax preference.
For investors who will be subject to the alternative
minimum tax, the tax benefits from R&D partnership deductions
could be reduced to as little as two percent. Additionally, longterm capital gains from R&D partnerships will continue to be
items of tax preference to the extent of the resulting capital gains
deductions. Consequently, the tax reasons for investing in R&D
partnerships will not apply to these individuals. For them, R&D
partnerships must be simply good business investments, with
any tax benefits simply an added feature. These investors will
probably view royalty partnerships as undesirable, and view equity partnerships as little different from any other conventional
venture capital investment.
With the passage of TEFRA, many people predicted that
R&D partnerships would die out. As a matter of fact, the
formation of privately-placed partnerships limited to a few large,
tax-motivated investors has virtually disappeared. However, the
growth of R&D partnerships is gaining new momentum with a
slightly different twist. Rather than large private placements
requiring minimum investments of $50,000 or more, publicly
placed partnerships requiring investments of as little as $5,000
are becoming popular. Not only do these lower amounts make
R&D partnerships available to a great many more investors, but
they allow investors to arrange their investments at levels where
the full tax benefits can be obtained.
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SECTION 5
IMPLEMENTING
A PROGRAM
The first step in any attempt to raise money is to develop
a strategic business plan for your proposed project. The business
plan will help you market your program and will serve as the foundation for the agreements and other documents that must be
drawn up. Just as important, the preparation of a business plan
forces you to focus on what you are trying to accomplish and to
analyze the costs involved.
A well-conceived business plan 3 is essential for an R&D
partnership program. Your plan should include the following
elements:
•

The project. Provide an extensive analysis of the R&D
project. Identify the specific technology to be developed,
the base technology that is available, and the personnel,
facilities and equipment required to complete the project.

•

Technical feasibility. Decide whether the technology is
possible, given the timeframe and budget you have established. To help market a project, many companies have
begun to use independent consultants or research firms
(such as SRI International) to perform a technical evaluation for them.

•

Market analysis. Estimate the potential demand for your
product. What are the existing and potential markets? You
should include assessments of your estimated revenues,
your estimated production costs, the competition you
may encounter, and the impact of alternate technology
and obsolescence on the technology you will be developing.

•

Development plan. Prepare a detailed budget explaining
the work to be done and the costs involved. Provide
benchmarks for the completion of the project.

3

Our first Entrepreneur's Guidebook - Raising Venture Capital - explains how to
write an effective business plan.
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•

Manufacturing and marketing plan. Once the project is
completed, how will the new product be manufactured
and marketed? Explain the costs of setting up
manufacturing facilities, where the funds will come from,
and what your marketing strategy will be.

•

Investment analysis. How will profits and losses be allocated? What cash flow can investors expect? What tax
consequences should they consider?

Once your plan is completed, your next step will be to
determine how you will market your program.

Finding Investors
Funding, probably the most difficult task in the entire implementation process, can be done through private placements
or public offerings.
If the amount of money to be raised is relatively small, you
may be able to raise the funds yourself through employees,
friends, relatives, and other contacts. Alternatively, some attorneys and accountants will assist clients in organizing small (up
to $500,000) R&D partnerships, not only to provide the clients
with funds to conduct necessary R&D, but also to provide tax
benefits to other clients of the law and accounting firms. If,
however, the amount of money to be raised is relatively large, you
should use an outside organization to help you locate investors.
The marketing of R&D partnership interests is done by various organizations, from small "professional general partner" groups to
the largest investment banking firms.
Firms of so-called "professional general partners" have
been popping up everywhere as R&D partnerships have become
more popular. These firms are generally willing to take on projects to raise anywhere from $500,000 to $4,000,000 for companies in need of R&D funds. Some, such as Technology Funding,
Inc. (San Mateo, CA), handle most of the technical matters necessary to organize the partnership, but raise the capital through arrangements with regional brokerage houses. Others, such as
Alpha Fund (Palo Alto, CA) and Crosspoint Venture Partners (Palo
Alto, CA), have blind pools already available for companies. R&D
Funding Corp. (San Jose, CA) recently teamed up with Prudential
Bache — while the former screens projects and assists with the
technical issues, the latter uses its retail brokerage network to
raise blind pool funds.
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Regional brokerage houses have been quite active
recently in raising from $1,000,000 to $16,000,000 through R&D
partnerships. Sutro & Co., Birr Wilson & Co., Inc., and Bateman
Eichler, Hill Richards, among many others, have been pursuing
R&D partnerships. Bateman Eichler raised its first pool of R&D
funds in November 1982 through a single R&D partnership to
provide funding for four separate, unrelated public companies; it
raised a second pool in December 1983 for five separate
companies, four of which are publicly traded.
National brokerage firms have also found R&D partnerships alluring. Merrill Lynch prefers deals in the $25,000,000 to
$60,000,000 range and up, although their recent Ventrex Technology Partnership was only a $15,000,000 program. E. F. Hutton,
which boasts the largest tax shelter business among the major
firms (some $700,000,000 in 1981), seems to prefer smaller R&D
deals in the $2,000,000 to $10,000,000 range. Oppenheimer & Co.,
which was one of the earliest explorers in R&D partnerships, now
apparently prefers programs of $20,000,000 or more.
After your plan is developed and you have decided how
and who will market your program, you can begin to have the
agreements, other essential documents, and the offering document drawn up. The documentation process is complex, and you
should use lawyers and accountants who have had prior
experience with R&D partnerships. Many of the major law and
accounting firms that serve high technology companies have
experience in this area.

Agreements
R&D partnership arrangements must be carefully structured to insure that the intended tax benefits actually result and
that both parties are adequately protected. R&D partnership arrangements involve an array of agreements, all of which are
generally executed concurrently.
Limited Partnership Agreement
The limited partnership agreement sets forth the terms
and conditions of the partnership itself. It provides the terms for
forming and dissolving the partnership; sets out the rights and
obligations of the limited partners; and defines the rights, obligations, authority, and responsibility of the general partner.
In those situations where the sponsoring company (or its
subsidiary or affiliate) is the general partner, the company faces
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potential conflict-of-interest problems. Management of the company has a responsibility to its shareholders; as the general partner, it also has fiduciary responsibilities to the limited partners.
Consequently, management may find itself in a position where it
cannot satisfy both parties. The best solution may be to have an
independent general partner. Companies reluctant to give up the
general partner role can establish a partnership with two general
partners - the company and an independent party.
The partnership agreement provides for the allocation of
profits and losses to the partners. Generally, almost all losses are
allocated to the limited partners to the extent of their investment.
Profits also are allocated almost entirely to limited partners until
such partners have recouped their investment. Thereafter, the
general partner shares in profits.

Figure 5-1: Agreements and Other Essential Documents

Investors

Base Technology Transfer Agreement
R&D
Partnership

R & D Contract
Technology License Agreement

Sponsoring
Company

Technology Purchase Option

R & D Budget
Project Feasibility Study
Opinion of Patent Counsel
Tax Opinion

Base Technology Transfer Agreement
In most cases, the sponsoring company will already have
completed some of the R&D work on the proposed technology.
The creator or the sponsoring company must transfer this base
technology to the partnership. If the technology is well beyond
the idea stage, the creator or sponsoring company may not want
to transfer all rights. To avoid doing so, the creator issues a base
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technology license to the partnership in exchange for a fee or a
cross license of partnership-developed technology to the sponsoring company. Generally, the license constitutes a non-exclusive, worldwide, royalty-free right to use for an indefinite term any
know-how which the creator or sponsoring company owns with
respect to the idea.
If the sponsoring company decides not to buy out the
partnership at the conclusion of the project, the partnership may
want to sell or license the technology to another company. In certain arrangements, the partnership cannot do this unless it has a
continuing license to the base technology. To protect the partnership in these instances, agreements can include a clause stating
that if the buy-out is not exercised, the company will license the
base technology to the partnership at a specified fee or at its
subsequent fair market value (as determined by arbitration).
Research and Development Contract
Typically, the sponsoring company agrees to do the
required research on a "best efforts" basis. Contracts usually
provide for payment of a fixed fee, or cost plus a fixed fee. This
payment is equal to the total funds of the partnership, net of organization and promotion costs and working capital requirements. For tax purposes you should establish the contract as an
arm's length transaction. To do this, the contract should provide
some reasonable profit to the company. The opportunity for the
company to have preferential rights to purchase the technology
on completion of the work might be deemed sufficient consideration, but the provision of a normal profit will give the arrangement
the flavor of a genuine contract research agreement rather than
an elaborate financing arrangement.
Under the contract, the partnership agrees to pay the entire R&D contract cost in advance or to make a substantial advance payment with the remainder to be paid in installments.
These advance payments are the basis for early deductions for
the limited partners. If the development period extends beyond a
year, however, it may be difficult to demonstrate a business purpose for prepaying everything "up front." In this case it would be
more prudent to call for installment payments as the project
progresses.
The company should agree to expend all funds received
from the partnership (other than its profit) only for items deductible as R&D expenditures under Sec. 174. The general partner
should monitor the expenditures periodically to satisfy its fiduciary responsibilities to the limited partners. Initial IRS attacks
on R&D partnerships have been to challenge the way the R&D
company uses the funds rather than to challenge the partnerships on more technical grounds.
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Under the contract, the partnership owns the patent
rights as well as all other technologies resulting from the
development process.
Developed Technology and Partnership Purchase Options
Royalty partnerships and some equity-type partnerships
give the sponsoring company an option to acquire the completed
technology from the partnership, or the partnership interests
from the partners, in exchange for royalties or a lump-sum buyout. Where the lump-sum buy-out is contemplated, the limited
partner often has an option to take cash, stock in the sponsoring
company, or both. It is important that the option to take stock
rests with the partners or the partnership; otherwise, the IRS may
apply the "disguised equity" doctrine (i.e., take the position that
the original payments to the company were, in reality, for the purchase of stock). In this case, the IRS would disallow the R&D deductions previously taken.
The royalty payments create a number of technical
problems which should be considered in the purchase option
itself. For example, there is the practical difficulty of determining
precisely which product sales should be subject to the royalty
payment. Suppose the technology is later integrated into other
products. Are sales of such future products subject to the royalty
payment, and, if so, should there be some formula to segregate or
apportion sales proceeds between a royalty element and a nonroyalty element?
If partnership interests will be converted into stock of a
new company, you may also face the "disguised equity" problem.
The agreement should provide that the partnership interests can
be converted only with a 2/3 affirmative vote of the limited partners. This requirement mitigates the appearance that the issuance of stock is a foregone conclusion.
Developed
Agreement

Technology

License

or

Joint

Venture

In order for a royalty partnership to meet the holding period requirements for long-term capital gains on the proceeds
received from selling the technology or partnership interest to
the sponsoring company, the partnership often must hold the
technology for a year before the sale. So that the sponsoring
company can use the technology immediately after development,
the partnership allows the company to use it under a developed
technology license agreement. Because of uncertainties as to
when the holding period begins on developed technology, the
period of the license should generally be for more than 12
months. At the end of this period, the purchase option is exercisable.
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If the joint venture arrangement
agreement is generally not executed.

is used, a license

Option to Acquire Stock
Occasionally the partnership will be given warrants to
purchase stock in the sponsoring company as part of the R&D
contract. Many brokers will tell you that this is essential with
some partnerships in order to market the limited partnership
interests. Investors may need to have some "equity play" to
entice them.

Other Essential Documents
In packaging an R&D partnership, there are various other
documents which may need to be prepared.
R&D Budget
The reasonableness of the R&D budget is extremely important. If too much money is raised because the budget is
excessive, the partnership risks loss of its R&D deduction. If too
little is raised, the difficult task of assessing partners or raising
an unscheduled second round of financing, with attendant tax
and logistics problems, comes into play.
As a result, every R&D partnership must have an R&D
budget that has been carefully prepared as part of the R&D contract. This budget demonstrates to everyone how the partnership
funds will be used and provides benchmarks on which the
research can be evaluated.
Project Feasibility Study
Even sophisticated investors will find it difficult to know
whether the technology is feasible; whether the product can be
manufactured on a commercially acceptable basis; or if manufacturable, whether the product can be marketed profitably. This is
particularly true of research and development in high technology
areas. Accordingly, independent written reports by one or more
reputable firms qualified to study such matters may be essential.
Opinion of Patent Counsel
If they can sell the technology pursuant to Sec. 1235,
royalty partnerships may be able to achieve long-term capital
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gains treatment without concern about the length of the holding
period. To qualify, the technology must at least be patentable and
should not be reduced to practice before the partnership's development work commences. Even where Section 1235 doesn't
apply, the "reduced to practice" issue is important in determining when the holding period starts. Essential documents for an
R&D partnership should, therefore, include the opinion of patent
counsel as to patentability and the "reduced to practice" issue.
Securities Opinion
The company should also assure limited partners that the
marketing of partnership units will comply with federal and state
securities laws. The documents of a well-organized R&D partnership should therefore include a securities opinion by knowledgeable attorneys.
Tax Opinion
As in most investments of this type, investors should
above all be confident that the venture makes good economic
sense. Since the ultimate economic return, however, will in large
part depend on whether the purported tax benefits will be realized, the company should provide the investors with a detailed
tax opinion by tax counsel or a CPA.
Three areas are normally addressed in the tax opinion:
•

the classification for federal income tax purposes of the
limited partnership;

•

the deductibility for federal income tax purposes of
payments made by the partnership to the sponsoring
company under an R&D contract; and

•

the character for federal income tax purposes of payments, if any, received by the partners pursuant to a
technology purchase agreement.

Aware of the uncertainties surrounding these tax issues,
many professionals are reluctant to give an opinion on them.
Even when they do, their opinions must be couched in wording
similar to the following:
"We have advised the General Partner that,
although the matter is not free from doubt, we
believe that the federal income tax benefits
described are, in the aggregate, more likely than
not to be realized by the investors."
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Some opinions have been silent on the issue of the buyout, which is the most difficult of the areas to structure properly.
In these instances, investors may need to assume their proceeds
will be taxed as ordinary income, and assess the offering price
accordingly.

The Selling Document
If you intend to publicly offer partnership units for sale,
you need to register with the SEC and prepare a prospectus. If
yours will be a private placement (limited to 35 nonaccredited investors and an unlimited number of accredited investors 4 ) you
need not register with the SEC, but you may need to prepare a
placement memorandum similar to a prospectus.
The prospectus or placement memorandum is intended
to provide potential investors with sufficient information to
assess the risks and merits of your offering.
The typical document includes:
•

A description of the R&D activities to be performed.

•

The use of the proceeds.(Other than to pay the R&D contract, proceeds might be used to pay underwriters' fees
and organizational costs and to provide the partnership
with some working capital.)

•

The significant risk factors.

•

The anticipated market for the products to be developed.

•

The anticipated competition.

•

Information about the sponsoring company, including
financial data, descriptions of key personnel, experience
related to the proposed project, etc.

•

A summary of the partnership and the partnership agreement, including an explanation of the allocation of profits
and losses.

•

Summaries of the R&D contract, base technology transfer
agreement, developed technology or partnership purchase option, license or joint venture agreement, and any
other agreements and essential documents related to the
R&D arrangement.

4

Accredited investors are generally institutional investors, certain company
insiders, and wealthy individuals.
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•

The tax opinion setting forth the probable tax consequences of the potential transactions, e.g., the deductibility of costs and the tax treatment of any proceeds to
the partnership.

Often, the prospectus will also present the potential cash
flows and taxable income to the limited partners if the project is
successful. Accompanying this information is a set of
assumptions used in preparing the projected amounts, so that
investors can answer such questions as what their rate of return
may be if sales are less than expected, if the project becomes
delayed, etc.

Ongoing Program Management
The final stage of the financing program is ongoing management of the partnership. This task usually falls on the general
partner who, as in other types of limited partnerships, is solely responsible for the management of the partnership. The general
partner must monitor the progress of the R&D contract work, distribute royalties, and provide progress reports and tax information to the limited partners.
In some of the partnerships that have been offered to
date, an affiliate of the sponsoring company has served as the
general partner. However, there is a strong trend toward general
partners that are completely independent of the company. An independent general partner protects the company from potential
conflict-of-interest problems and removes the partnership bookkeeping burden from management.
The amount of time and effort required to implement an
R&D partnership financing program can be substantial and can
divert significant management resources from the primary business of the company. This time and effort can be greatly reduced
by utilizing investment bankers, R&D partnership service firms,
accountants and lawyers with expertise in partnership financing.
These experts can efficiently accomplish the implementation
tasks, so that your company can realize the full benefits of the
R&D partnership program.
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CASE STUDIES
Syntex Diagnostic Limited
Partnership
Trilogy Computer Development
Partners, Ltd.
Genentech Clinical Partners, Ltd.
Diversified Technology Partners,
Ltd. — 1 9 8 2
Alpha Partners
Beta Partners
G a m m a Partners

SECTION 6
CASE STUDIES
R&D partnership arrangements have few limitations. They
can be of any dollar amount. They can be sold privately or publicly, locally or nation-wide. They can have royalty agreements, or
they can have cash, equity, or cash-and-equity buy-out agreements. To illustrate this flexibility, we present in this section examples of seven R&D partnerships which have been formed:
•

Syntex Diagnostic Limited Partnership — a private
offering to raise funds to develop five different medical
products for an established public company.

•

Trilogy Computer Development Partners, Ltd. - a public
offering to provide funds to a private start-up company.

•

Genentech Clinical Partners, Ltd. - a public offering for an
emerging public company, designed with a long-term
joint venture arrangement.

•

Diversified Technology Partners, Ltd. - a public offering to
raise a pool of funds for four public companies.

•

Alpha Partners - a private offering to provide seed money
and, later, a second round of financing for a start-up
company.

•

Beta Partners - a small private offering to provide financing for a second product for an emerging private
company.

•

Gamma Partners - a start-up company organized as a
partnership.
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Syntex Diagnostic Limited Partnership
In November 1982, Syntex Corporation used an R&D partnership to raise funds for the development of five different medical diagnostic products.
Syntex is an international life sciences company that
develops, manufactures and markets a wide range of health and
personal care products. For fiscal 1982, its net income was $134
million on sales of $813 million. Syntex medical diagnostic products, such as those to be developed using partnership funds,
are developed and marketed through Syva Company, a wholly
owned subsidiary.
In the partnership prospectus, Syntex indicated that partnership funds would allow funding of more projects than otherwise might be pursued because of financial considerations. Its
R&D expenditures for fiscal 1982 were $84 million, or 10.3% of
sales.
Size of offering — $23,500,000.
Investment bankers — Allen & Company, Lehman Brothers Kuhn
Loeb and Merrill Lynch White Weld Capital Markets Group.
Minimum investment — $100,000, payable all in cash, or $8,300 in
cash and the balance in a promissory note payable as follows:
$28,500 in 1983, $23,300 in 1984, $31,200 in 1985, $5,300 in 1986
and $3,400 in 1987.
Net proceeds to partnership — $20,885,000 (net of placement
fees of $1,645,000, financial advisory fees of $470,000 and offering expenses of $500,000). Upon consummation of the offering,
the Partnership would borrow $2,583,000 from Syntex to pay substantially all fees and expenses related to the offering and
$2,000,000 from Merrill Lynch Interfunding for certain first-year
research and development expenditures. The investor notes are
pledged as collateral for these loans.
Partnership agreement — benefits to be allocated 99% to the
limited partners and 1% to the general partner.
Cross license agreement — Syva provides the partnership with a
limited, exclusive, worldwide license to use the base technology
for the term of the development agreement and agrees to provide
this license to any third party to which the partnership might
transfer the technology in the event that Syva does not exercise
any of its options. In exchange, the partnership grants Syva a
license to use the developed technology for purposes other than
the five specific products to be developed by the partnership.

Development agreement — Syva is to perform the research and
development work for a fee allocated to the project as follows:
Funding from the partnership:
SQST Instrument and Module
APRS Instrument
Advance II Instrument
Penicillin Dipstick Immunoassay Kit & Reader
Blood Typing Kit and Instruments
Total partnership funding
Funding from Syntex:
Blood Typing Kit and Instruments
Total development fees

$ 2,200,000
2,000,000
3,400,000
4,200,000
7,450,000
19,250,000
4,100,000
$23,350,000

Syva may reallocate funds among the projects, and excess funds
on any completed project may be reallocated to other projects.
Development fees allocated to the Blood Typing project total
$11,550,000. The first $3,350,000 of the project will be funded by
the partnership. The remainder will be funded equally by the
partnership and by Syntex. The funding from Syntex is in the form
of a mandatory loan up to a maximum of $4,100,000. This loan will
be repaid only if the Blood Typing project is successfully
completed and only from partnership revenues attributable to the
project.
Syntex' total commitment under the mandatory loan is
$4,600,000. Any amounts not lent to the Blood Typing project
shall be made available, if necessary, to complete development
of the other four projects. Repayment of such amounts is not
dependent on successful completion of the projects.
Interim license — During the periods between the completion of
the projects and the dates the purchase options are exercisable,
Syva may use the developed technology and products in return
for royalties of 7-10%, depending on the product.
Option agreements — Syva has an option to purchase the
partnership's rights in the base technology and the developed
technology of each of the five products. The options are
exercisable between twelve and fifteen months after the project
completion dates. Purchase is in the form of royalties of
generally 8% to 11%, depending on the product. For the Blood
Typing product, royalties are payable until December 31, 2000 or
until royalties equal $75,000,000, whichever occurs first. For the
other four products, royalties are payable for eight years, until
December 31, 2000 or until royalties equal $75,000,000, whichever
occurs first.

The initial loans from Syntex and from Merrill Lynch
Interfunding were made to facilitate cash flow in the early years
of the projects, since the partnership units were payable in
installments.
Because this partnership encompasses five separate
projects, the risk to the investors may be reduced — if any one
project is unsuccessful, the investors can still look to four other
projects for a potential return on their investment.
Syva estimated that the risks associated with the Blood
Typing project were substantially greater than the risks for the
other projects, primarily because Syva had no experience in
developing tests for the blood banking market and had limited
marketing capabilities to reach that market. Consequently, the
arrangement was structured so that Syntex shared that greater
risk, up to a maximum of $4.1 million.
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Trilogy Computer Development Partners, Ltd.
Trilogy Limited is a Bermuda holding company, organized
in September 1980. Trilogy Systems Corp. is its wholly-owned
subsidiary, organized in August 1980. In August 1981, the companies used an R&D partnership to raise funds to design a large
scale, high performance, general purpose computer system.
The companies had no operating history — since formation, Trilogy Limited had engaged primarily in raising capital and
organizing the corporate structure, and Trilogy Systems Corp.
had engaged primarily in obtaining facilities and recruiting personnel to begin development of the computer design. In its prospectus, Trilogy Limited estimated that it would be competing in
a $7 billion market by 1985.
Size of offering - $55,000,000.
Investment banker - Merrill Lynch White Weld Capital Markets
Group.
Minimum investment — $10,000 (2 units of $5,000 each).
Net proceeds to partnership Limited partners' contribution
General partner's contribution
Selling commissions and fees
Other expenses

$55,000,000
555,556
55,555,556
(3,850,000)
(641,000)

Net proceeds

$51,064,556

Partnership agreement - profits and losses to be allocated 99%
to the limited partners and 1% to the general partner.
Technology license agreement - Trilogy Limited grants the
partnership an exclusive, world-wide, royalty-free license to use
its base technology.
Development contract - Trilogy Systems Corp. will perform the
development work at cost plus a profit varying from 0-15% of
cost, as determined by a formula.
License agreement - Trilogy Limited has the option, exercisable
one year and one day after the technology is reduced to practice,
to acquire an exclusive, worldwide license to use the computer
design and sublicense it to others. The option does not expire until 1988. Trilogy Limited will pay royalties of 7.7% to the limited
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partners until payments equal $110 million, and thereafter,
royalties of 3.3% or 11% of the pre-tax profits of Trilogy Limited,
whichever is greater. Alternatively, Trilogy Limited may make a
lump-sum payment equal to the greater of: (1) $220 million less
royalties to date, or (2) $110 million. The partnership may elect to
take 6,875,000 shares (as adjusted for a subsequent 4:1 stock
split) of Trilogy Ltd. common stock in lieu of cash, or to take a
combination of stock and cash.
The buy-out option, if exercised by Trilogy Limited, allows
the investor to take either cash or stock. The option for stock was
given as an added inducement to the investors. The lump-sum
buy-out declines over time to take into account any royalties paid
in the interim. However, the number of shares which the partners
may take in lieu of cash does not decline. If the project is successful and Trilogy anticipates that the stock will be taken in lieu
of cash, it would be to Trilogy's advantage to exercise its option
as soon as possible to avoid the payment of royalties.
At the time of the offering, Trilogy Limited had 20,746,668
shares of common stock and equivalents (convertible preferred)
outstanding. Consequently, at the time of this offering the
partnership interests could be converted to a 25% equity interest
in the company.
In June 1983, additional funds for the project were raised
through an equity offering. In early 1984, in a move to prepare
itself for raising still more funds for the project, Trilogy
announced its intention to offer to purchase the outstanding
partnership units in exchange for Trilogy Ltd. common stock. The
buy-out ratio of 625 shares per unit was the same as the stock
buy-out ratio in the original purchase option agreement, so that
the effective cost to the limited partners for the stock received
was $8 per share, less any tax benefits they derived from their
initial investment. At the time Trilogy announced it would make
the purchase offer, its stock was trading at approximately $8 per
share.
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Genentech Clinical Partners, Ltd.
In November 1982, Genentech, Inc. used an R&D partnership to raise funds to clinically test and develop manufacturing
processes and alternative delivery systems for human growth
hormone ("hGH") and gamma interferon.
The company has been in existence since 1976. Its main
activity has been research and product development. During its
development period, the company has tried to minimize its
losses by covering operating expenses with revenue from research and development contracts with customers. Under these
contracts, the customers generally receive manufacturing and
marketing rights in exchange for payments to Genentech for
research costs and for royalties upon the ultimate sale of the
products.
In 1979, Genentech sold $10 million of preferred stock; in
1980, it sold $38 million of stock in an initial public offering; and in
1982, it sold $10 million more of equity. These funds were to be
used primarily to acquire facilities and equipment and to fund
working capital.
Size of offering - $55,000,000.
Investment bankers
Hambrecht & Quist.

-

Blyth

Eastman

Paine

Webber

and

Minimum investment - $100,000 payable in five installments over
3-1/2 years.
Net proceeds to partnership Limited partners' contribution
General partner's contribution

$55,000,000
500,000
55,500,000
(4,950,000)
(550,000)
$50,000,000

Selling commissions and fees
Other expenses
Net proceeds

Partnership agreement - Profits and losses to be allocated 99%
to the limited partners and 1% to the general partners.
Cross license agreement - Genentech makes available its base
technology in exchange for royalty-free license to patents and
know-how for all purposes other than use in the United States.
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Development contract - Genentech will perform the development
work at cost plus a retainer fee of up to $3,600,000.
Option agreement - Upon FDA approval of the first product,
Genentech has the option to enter into a joint venture with the
partnership to manufacture and market the products. The partnership will receive 22% of the joint venture's profits and losses. After the earlier of (a) four years or (b) two years and the allocation
of $8.25 million of profits to the partnership, Genentech may purchase the partnership interests. The purchase price will be 7% of
sales until payments equal $55 million, then 5% of sales until
payments equal $110 million, and 3% thereafter until June 1998,
with minimum royalties of $1 million per quarter for the first 12
quarters. Genentech has the right to buy out the payment obligations for stock, cash, or other consideration, upon acceptance of
the terms by 80% of the investors.
In its business plan, Genentech projected that the joint
venture would be formed in January 1984 and that sales of hGH
and gamma interferon would be $8.1 billion through June 1998.
Note that Genentech has the option to purchase the partnership
interests rather than the technology (as seen in earlier R&D
arrangements). From a tax standpoint, practitioners have
generally found buy-outs of partnership interests, rather than
buy-outs of the technology, easier to qualify for long-term capital
gains treatment.
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Diversified Technology Partners, Ltd. - 1982
Bateman Eichler, Hill Richards sponsored Diversified
Technology Partners, Ltd. - 1982 to fund R&D projects for four
separate publicly-held companies. The partnership's stated
investment objectives were:
(1) To return Limited Partners at least 300% of their contributed capital (exclusive of tax benefits) over an
eight (8) year period
(2) To generate current year tax deductions to Limited
Partners in excess of 90% of their contributed capital;
and
(3) To generate royalty income from sale of any successfully developed partnership technology, substantially
all of which will be eligible for long-term capital gains
tax treatment.
Based on these objectives, the partnership selected the
following four projects:
1)

Anderson Jacobson, Inc.
Project: Voice/Data PBX System
Revenues in last fiscal year: $50 million
Product's potential for sale: $780 million through 1990

2)

Quixote Corporation
Project: Laser videodisc mastering and replication
process
Revenues in last fiscal year: $20 million
Product's potential for sale: $325 million through 1990

3)

Digilog, Inc.
Project: Data line monitors/simulators
Revenues in last fiscal year: $8 million
Product's potential for sale: $150 million through 1990

4)

Velo-Bind, Incorporated
Project: Proprietary Office Product
Revenues in last fiscal year: $19 million
Product's potential for sale: $98 million through 1990

Size of offering - $16,650,000.
Minimum Investment - $5,000.
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Proceeds to partnership Limited Partners
General Partner (a limited partnership, in which
the four sponsoring companies are limited
partners who have contributed $1,948,500; the
general partner is an affiliate of Bateman
Elchler, Hill Richards)

$16,650,000

1,948,500
18,598,500
(1,332,000)
(766,500)
$16,500,000

Selling commission
Other expenses
Net

Partnership agreement - profits, losses, and cash distributions
will be allocated before and after payout (receipt by the limited
partners of cash distributions equal to their capital contributions)
as follows:

Before payout
After payout

Limited
Partners
95%
85%

General
Partners
5%
15%

License agreement - companies grant the partnership a royaltyfree non-exclusive license to use the base technology during the
term of the R&D agreement.
Development agreement - companies will perform the development at cost plus a 10% profit factor. Contract prices are as
follows:

$ 8,800,000

Anderson Jacobson, Inc.
Quixote Corporation
Digilog, Inc.
Velo-Bind, Incorporated

4,000,000

2,000,000
1,100,000

$15,900,000

Option Agreements-The companies each have an option to enter
into joint ventures with the partnership to manufacture and market the new products. Joint venture profits will be split between
the company and the partnership 80%-20%, respectively, for the
first 14 months and 60%-40% thereafter. The companies are
committed to loan the joint venture up to the following amounts,
as required by each joint venture:
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Anderson Jacobson
Quixote
Digilog
Velo-Bind

$5,000,000
2,500,000
1,400,000
2,600,000

If the companies exercise their joint venture option, they then
have an option to purchase the technology 13 months after the
first product is shipped or the invention has been "reduced to
practice."
Royalties are payable for 10 years, on a graduated scale as
follows:
Anderson Jacobson: 8% reduced gradually until sales reach $766
million, and 5% thereafter;
Quixote: 20% reduced gradually until sales reach $162 million,
and 2% thereafter;
Digilog: 7% reduced gradually until sales reach $116 million, and
2% thereafter;
Velo-Bind: 9% reduced gradually until sales reach $47 million,
and 2.5% thereafter.
The pooled fund offered many advantages to both the
sponsoring companies and the investors. The companies probably could not individually sponsor R&D public offerings, as the
projects were not large enough and the companies not wellknown enough to make individual offerings marketable. The
investors have the advantage of diversification - their risk is
spread among four separate projects.
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Alpha Partners
Immediately after Alpha, Inc. was established, the founders formed an R&D partnership. Their intent was to use the partnership funds as seed money for the first year of operations,
primarily to complete development of a family of advanced
computer systems.
Round I
Proceeds to partnership - Limited partners to contribute $800,000
payable in installments over 8 months; general partner (Alpha,
Inc.) to contribute base technology (valued at $13,000) plus
$5,500.
Development agreement - Alpha, Inc. will perform the required
development work in exchange for $750,000.
Partnership agreement - Profits to be allocated 37% to the general partner and 63% to the limited partners; losses to be allocated
100% to the limited partners to the extent of their contributions,
and thereafter in accordance with the profits allocation.
After eight months, a second round of financing was
sought. The company decided not to seek a different source of
financing. Instead, the partnership agreement was revised to
admit two additional classes of partners.
Round II
Proceeds to partnership - $4,000,000 from Class B limited partners and $1,000,000 from Class C limited partners, payable in
installments over 13 months.
Development agreement - Alpha, Inc. will perform the required
development work in exchange for $4,000,000.
Partnership agreement - Profits and losses to be allocated as
follows:
(1) R&D expenses - first $750,000 to Class A (already
spent and allocated); second $4,000,000 to Class B;
third $50,000 to Class A again; and the remainder to
the general partners.
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(2) Other losses - first $52,000: 96% to Class A, 1% to
Class C, and 3% to general partner; second $52,000:
96% to Class B, 1% to Class C, and 3% to general
partner until Class B partners receive a total allocation of $4,000,000; thereafter, 1 % to Class C and 99%
to general partner.
(3) Profits: 44.10% to Class A, 23.08% to Class B, 6.92%
to Class C and 25.90% to the general partner.
In both arrangements, the contracts were silent as to the
disposition of the technology. The partnership provides that it
will incorporate at some point only if the incorporation is approved by 2/3 vote of the limited partners. Presumably, new
shares will be issued based upon the partners' relative profit
allocation.
In Round II, the partnership sold a 30% interest for
$5,000,000. The general partner's and the Class A partners' profit
participation were reduced proportionately. The Class C partners
were offshore investors who had no need for U.S. tax deductions;
consequently, allocations of losses to Class C partners were
minimal (1% of residual losses). However, the Class C partners
paid approximately 20% less for their investment than did the
Class B partners.
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Beta

Partners

Beta Company was founded in 1975. In July 1981, it had
completed development of a major new product and was
spending substantial amounts to develop its marketing network,
install production equipment, and fund higher inventory and
receivables levels. Beta Company had begun development on a
second related product, and estimated that it would require
$250,000 to complete that development. Although the company
had access to a bank line of credit, the prime rate at that time was
approximately 20%. Beta Partnership was formed to finance the
remaining development.
Proceeds to partnership - General partner (Beta Subsidiary) to
contribute $2,500; limited partners to contribute $250,000 in two
installments.
Development agreement - Beta Company to develop the new
product no later than October 1982 for $250,000.
Partnership agreement - Losses to be allocated 99% to the
limited partners and 1 % to the general partner until allocations to
the partners equal $250,000. Thereafter, losses to be allocated
1 % to the limited partners and 99% to the general partner. All income to be allocated 99% to the limited partners and 1% to the
general partner.
License and purchase option agreement - The company has the
option to acquire an exclusive license for a maximum term of 14
months in exchange for royalties of 10% of sales up to a maximum of $210,000. At the end of the license term, the company has
an option to purchase the technology from the partnership for
royalties of 10% of sales (subject annually to maximum cumulative amounts and subject to an aggregate amount of $715,000) or
a lump-sum payment. The lump-sum payment is based upon
royalties paid through the date of the lump-sum payment and is
also subject to a maximum of $715,000.
The payments were designed to provide the investors
with an annual 45% return on their net investment. For example,
in the first year, there was a maximum royalty payable of
$210,000. In the second year, the maximum was $120,000 plus
145% of any amount by which first-year royalties were less than
$210,000.
The company found the project less difficult than it had
anticipated, and in January 1982 it was already contemplating
how to consummate the buy-out. Beta Company had no cash,
however, and began a few months later to negotiate an equity or
equity plus cash buy-out with the investors.
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The investors agreed to an early buy-out at a price that
would provide them with a 45% after-tax rate of return. However,
they were not interested in an equity buy-out unless the transaction could be structured as tax-free.
The buy-out was structured as follows:
(1) The partnership transferred its technology to Beta
Subsidiary in exchange for 26,993 shares of Beta Subsidiary. The shares were valued at $229,000 and
represented 20% of the outstanding stock as of
November 1982 (the date of the buy-out).
(2) Simultaneously, Beta Company transferred a $125,000
note to Beta Subsidiary in exchange for sufficient
shares to bring its total shares held to 80% of the
total.
(3) Beta Company received a "call" option on Beta Subsidiary stock which provided for the exchange of Beta
Subsidiary stock for Beta Company stock on a onefor-one basis. Similarly, the partners received a "put"
option providing for the same exchange in case of
certain events, such as a public offering.
The transaction is designed to be a tax-free transfer under
Sec. 351, as immediately after the exchange, the parties transferring property (the prototypes and the note receivable) were in
control (owned more than 80%) of the subsidiary. Beta
Company's share of Beta Subsidiary was structured to be 80% of
the total so that the company could consolidate the subsidiary
for tax purposes.
The result to the company of the R&D program was the
receipt of $250,000 cash in exchange for the issuance of only
$229,000 of stock sixteen months later!
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Gamma Partners
Gamma Partners was formed to develop and manufacture
advanced communications products. The founder is the general
partner and a venture capital group is the limited partner.
Proceeds to partnership - The general partner to contribute all its
right, title, and interest in and to any and all technology, knowhow, proprietary information, materials and products in respect
of the communications product. Such contribution will have an
agreed value equal to $11,000.
Limited partner to contribute $110,000 initially for Phase I and to
make additional contributions for subsequent phases, if and
when certain milestones are satisfied. Total contributions will be
as follows:
Phase I - Prototype will be produced and market
viability will be proven

$110,000

Phase II - Production and shipment will reach
prescribed levels and field trials will be
underway at three or more key customers

190,000

Phase III - Management team will be in place;
marketing, financial, and business development
plans will be completed; and cumulative shipments and a backlog will reach prescribed levels

370,000
$670,000

Partnership agreement - Losses to be allocated 99% to the
limited partner and 1% to the general partner until the limited
partner has been allocated aggregate losses in an amount equal
to its capital contributions; thereafter, in accordance with the
profits allocation. Profits to be allocated as follows:
During
Phase I

During
Phase II

During
Phase III

75%
25%

65%
35%

55%
45%

General Partner
Limited Partner

This arrangement reduces the risk for the investor. Rather
than investing $670,000 all at once, the investor contributes in increments. If the project does not progress as well as anticipated,
the investor can walk away with a smaller loss.
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In actuality, there will be no profits to allocate. But the
profit allocation shows how the limited partner's ownership increases as he makes additional contributions. Based on those
contributions, the company is assumed to be valued as follows:
Phase I - $440,000 ($110,000 for a 25% ownership interest)
Phase II - $1,900,000 ($190,000 for an additional 10% interest)
Phase III - $3,700,000 ($370,000 for an additional 10% interest)
After Phase III was completed, the company incorporated
and sold additional stock for its second round of financing, at
which time the company was valued at $5,500,000.
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APPENDIX I
TAX CONSIDERATIONS FOR
THE PARTNERSHIP
The tax treatment of R&D partnerships is rife with uncertainties. Many issues must be considered at the time the R&D
arrangements are drafted in order to provide the most favorable
tax treatment for the investors. Such issues include:
•

the structure of the partnership,

•

the deductibility of R&D expenses,

•

the deductibility of other partnership expenses,

•

the sale of the technology, and

•

the availability of research and experimentation credits.

The Structure of the Partnership
A number of issues not necessarily peculiar to R&D partnerships must be considered by all tax-oriented limited partnerships when designing the structure of their organizations. Many
of these issues were raised by the IRS in rulings on whether
certain partnerships could be classified for federal income tax
purposes as partnerships rather than associations taxable as
corporations.
In requests for advance rulings, the IRS has indicated that
it will provide a favorable ruling if the following factors exist:
•

The limited partners own no more than 20% of the
general partner, including ownership attributed under the
rules of Code Sec. 318.

•

The general partner has at least a 1% interest in profits
and losses of the partnership, not including any limited
partnership interests that the general partner might hold.

•

Losses to the partners during the first two years will not
exceed the equity capital invested.

•

If the total capital of the R&D partnership is less than $2
million, a sole corporate general partner has net worth
equal to 15% of the total partnership capital or $250,000,
whichever is less. (Net worth is computed based on the
current fair market value, rather than book value, of the
general partner's assets, and excludes the general
partner's investment in the limited partnership.) If the
total R&D partnership capital is more than $2 million, the
sole corporate general partner should have net worth, not
including its partnership interest, equal to 10% of the
R&D partnership capital.

•

The purchase of limited partnership interests in the R&D
partnership does not include any purchase options (e.g.,
warrants) to acquire any type of security of the corporate
general partner.

•

In the event the R&D partnership has nonrecourse creditors, those creditors do not get an interest in the R&D
partnership in exchange for the loan.

The IRS will consider all of these factors in deciding
whether to provide the partnership with a favorable ruling. If one
or more of these factors does not exist, the IRS will probably not
provide any ruling. The lack of a favorable ruling, however, will
not necessarily preclude the partnership structure from
producing the desired tax results for the partners.

Deductibility of R&D Expenses
Sec. 174 of the Internal Revenue Code of 1954 (the
"Code"), as amended, provides that "a taxpayer may treat
research and experimental expenditures which are paid or incurred by him during the year in connection with his trade or
business as expenses" which are allowed as current deductions.
Definition
The partners' deductions depend on whether their funds
are to be used for research and development. Unfortunately, the
Code and related Regulations provide only a little insight on the
definition of R&D expenses. The regulations state that "research
or experimental expenditures" include all research and development costs (in the experimental or laboratory sense) incurred to
develop an experimental or pilot model, a product, or an inven-

tion. The term also includes costs to improve an existing model,
product, or invention. 1 The costs of obtaining patents (e.g., legal
fees), as well as the costs of perfecting title or defending the
patent against attack, can also qualify under Sec. 174.2 Although
the cost of capital equipment, other than supplies, does not
qualify for R&D expense, depreciation of the equipment does. 3
A base technology transfer or license agreement allows
the R&D partnership to use this base technology in the R&D effort. Payments to acquire title to the technology probably will not
qualify for a deduction under Sec. 174, but periodic payments
made under a technology license agreement are considered deductible expenses under that provision. The base technology
license must be carefully drafted. If the license term is too long
(e.g., in excess of the useful life of the technology), the license
payments may be characterized as expenditures to "acquire"
technology.
In addition, some expenses that are typically viewed as
R&D costs in common parlance do not qualify for a deduction:
•

Cost for ordinary testing or inspection of materials or products for quality control do not qualify. However, testing
and inspection costs incurred in building the prototype
do qualify.

•

Efficiency surveys.

•

Management studies.

•

Consumer surveys.

•

Advertising or promotions.

•

Cost of acquiring another's patent, model, production or
process.

•

Research regarding literary, historical or similar projects.

•

Cost of land or depreciable property used in the R&D
effort (although the depreciation does qualify).

1 Regs. Sec. 1.174-2(a)(1).
2 Rev. Rul. 68-471, 1968-2 CB 109.
3 Regs. Sec. 1.174-2(b)(1).
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Because these costs are often incurred during the term of the
R&D contract, they may mistakenly be treated for tax purposes as
R&D expenses. Care must be taken to prevent the use of partnership R&D funds for such expenditures. The research contract
should specifically state that no partnership funds will be expended for any nondeductible R&D costs. If the partnership
funds are the sponsoring company's only source of capital, these
nondeductible items should be paid for with the profits from the
R&D contract.
When taxpayers do not acquire an ownership right in depreciable property and the property is used in connection with
research and development, the entire cost of the property is deductible under Sec. 174. Therefore, the R&D contract typically
provides that the sponsoring company will acquire the required
equipment and will also receive title to that equipment. As long
as the R&D partnership has no ownership rights in the property,
the partnership can deduct the amount of funds paid over to the
company even if those funds are used to acquire equipment. The
R&D contract should clearly state that all tangible assets
acquired for the research belong to the sponsoring company.
A more difficult issue arises when the prototype is not
built until all the abstract research and development has been
completed. The regulations suggest that the actual costs of
material, labor, etc., to build the prototype do not qualify for the
Sec. 174 deduction. 4 The partnership may have a stronger argument for deducting these costs if the R&D contract states that
the prototype will belong to the sponsoring company and be
leased by the partnership, although this approach has not yet
been tested in court.
Risk of and on Behalf of the Taxpayer
To qualify for a Sec. 174 deduction, the research must be
conducted at the risk of the partnership, 5 and it must be performed for the partnership's benefit. 6
If the sponsoring company guarantees that it will produce
the desired technology or product, the research is not considered
as being conducted at the partnership's risk. If the company,
however, guarantees that the research and development will be

4

Regs. Sec. 1.174-2(b)(4).

5

Regs. Sec. 1.174-2(b)(3).
Regs. Sec. 1.174-2(c)(2).

8

performed pursuant to agreed specifications, the guarantee will
not disqualify the R&D expenses, because the partnership still
bears the risk for the overall results.
Many developed technology purchase options require the
sponsoring company to pay minimum royalties to the partnership
in exchange for the technology, regardless of the success of the
selling effort. Some experts view minimum royalties as essential
to insure that the sponsoring company makes a strong marketing
effort. Otherwise, the company may drop the new product in favor
of a more profitable one.
Minimum royalties may, however, be perceived by the IRS
as reducing the partnership's risk. Consequently, they should be
used with caution. Minimum royalties equal to a small
percentage of the partners' capital investment may be
permissible, as the partners would remain substantially at risk.
But in most cases, even minimum royalties should be avoided if
possible. Instead, the documents should be drafted to indicate
that if the research is totally unsuccessful, the partnership will
lose its entire investment in the research. 7
Cash vs. Accrual Basis Partnerships
The Sec. 174 deduction is available to both cash and
accrual basis partnerships. For tax purposes, most R&D partnerships use the cash basis of accounting. On this basis, partnerships can take deductions when a payment is made, provided
that the payment is non-refundable except in cases of a breach of
contract.
The accrual method could accelerate the deductions of
the limited partners, resulting in deductions in excess of the
partners' actual out-of-pocket investment.
Accrual basis partnerships are allowed the R&D
deduction when the liability is fixed, i.e., when the R&D contract
is signed. However, several requirements must be met before an
accrual basis partnership can accrue a liability:
•

The liability must be legally binding and enforceable.

•

The liability cannot be contingent on some future event,
such as performance of other services by the sponsoring
company. For example, the R&D contract cannot provide
that the liability will be reduced or funds returned to the
partnership if the sponsoring company is not able to
reach certain contract milestones.

7

For additional discussion of the "risk of taxpayer" requirement, see Rev. Rules
73-275, 1973-1 CB 134, and 73-20, 1973-1 CB 133.
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•

The obligation must be certain in amount.

•

A substantial number of cases indicate that there must be
reasonable belief on the part of the debtor that the liability will be paid. 8 Nevertheless, the structures of many
"tax shelters" (including some R&D partnerships) imply
that no one expects the accrued liabilities to be paid. For
example, contract arrangements of many accrual basis
R&D partnerships provide for the indebtedness to be paid
from royalties. Under case law, these arrangements
appear to lack sufficient basis for accruing the liability.

Sec. 465 of the Code limits the partners' deductions to
the amount the partners are at risk at the end of the partnership's
fiscal year. Accordingly, for accrued expenses to be deductible,
partners must also be personally liable under the R&D contract.
When the partnership is formed, the limited partners
should give full recourse notes to the partnership in an amount
equal to the additional contributions the limited partners are
obligated to make to pay off the accrued expenses. Requiring the
partners to also provide back-up letters of credit adds substance
to the recourse note arrangement. Ideally, the partners should
pay off their notes within a short period of time; otherwise, the
IRS may question the need for these amounts for R&D.
Arrangements which call for recourse notes with maturity dates
several years into the future or beyond the anticipated
completion date of the R&D project should not be used. Instead,
the sponsoring company could borrow against the notes to
obtain the funds for the research. However, most commercial
lenders are not willing to extend credit on this basis.
A cash basis partnership could also provide its partners
with deductions in excess of the partners' investment if the partnership rather than the company borrowed against the partners'
notes and then gave the proceeds to the sponsoring company. A
recent Merrill Lynch partnership, Ventrex, used this approach.
But Merrill Lynch, rather than a more conventional commercial
lender, loaned the funds to the partnership.
Prepayment of R&D Contract Costs
Prepayment of R&D contract costs by a cash-basis
partnership allows the limited partners to obtain "up-front"
deductions. That is, the partners can obtain deductions before
any substantial amount of research under the contract has taken
place. The deductions are available in the year of the investment,
even if the investment is not made until very late in that year.
8

See, e.g., Putoma Corp., 66 TC 652 (1976); United Control Corp., 38 TC 957 (1962),
acq., 1966-1 CB 3; Dixie Pine Products Co., 320 US 516 (1944) (31 AFTR 956, 44-1
USTC para. 9217).
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Rulings on expenses other than research and development (e.g., prepaid fee deductions) indicate that a prepaid
expense must meet several requirements before it can be deductible by a cash-basis taxpayer:
•

The prepayment may not be a deposit. To prevent the
prepayment from being classified as a deposit, the R&D
contract must specifically require that prepayment be
made to the sponsoring company before any services are
rendered. 9 To avoid any inference that such payment is
contingent, the contract should also state that the obligation to pay is independent of the obligation to perform
services. Further, the prepayment must be nonrefundable, except for a material breach of the contract.

•

The prepayment must have a business purpose. A number
of good business reasons may favor prepayment of the
contract fee. For example, most contract R&D firms will
not grant credit to a new company with an untried process
or product idea. If the sponsoring company is a new enterprise, the funds from the R&D partnership may constitute its only source of capital. Likewise, the company
may need to hire several skilled personnel to fulfill the
contract. These people may need assurance that they will
be employed for a certain length of time and that the
funds to compensate them are currently available. Similarly, vendors may need assurance that they will be paid
before they agree to deliver materials and equipment
crucial to the project. Prepayment also allows the R&D
company to order materials in efficient quantities.

•

The prepayment must not result in a material distortion of
income. The "distortion of income" test is not troublesome for R&D partnerships, because Sec. 174 expenses
are exempt from the capitalization requirement of Sec.
263. In addition, R&D costs appear to resemble product
costs more closely than the period costs (such as prepaid
rent or prepaid insurance) to which the distortion of income test is usually applied. Nonetheless, cash-basis
partnerships should not prepay R&D costs for a period of
work in excess of one year.
The Zaninovich ruling 1 0 sanctions the current deduction

9

George Cheroff, TC Memo 1980-125.

10 Martin J. Zaninovich, 616 F2d 429 (9th Cir. 1980) (45 AFTR2d 80-1442, 80-1 USTC
para. 9342).
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of prepayments not covering periods in excess of one
year, and provides the partnership with additional support
for a current deduction. There is also a practical reason
for making payments in installments — the general
partner can monitor the project's progress before making
the next payment and thereby have some additional
leverage over the sponsoring company.
In early 1984, legislation was proposed to prohibit a partner in a cash basis partnership from taking a current deduction
for payments under a development contract until the development is actually performed by the company. If the legislation is
enacted, it will preclude the deduction for prepaid development
expenses for a partner in a cash basis partnership.
Reimbursement of Pre-contract Costs
Partnership organizers frequently incur expenses before
any contract is signed with the sponsoring company, and then
seek reimbursement from the partnership. For the partnership to
get a deduction under Sec. 174, the pre-contract work must be
performed on the partnership's behalf and at its risk.
If substantial R&D work took place before formation of
the partnership and execution of the R&D contract, the
partnership should license the work from the person who
conducted the research, rather than reimburse the individual for
the costs, because this pre-contract work may not be viewed as
performed "on behalf of the partnership." The license fee should
be deductible if: (1) the partnership's use of the technology is
limited to the purpose and duration of the partnership effort; and
(2) the partnership does not acquire ownership of the technology.
Where only a little pre-contract work occurs before the
formation of the partnership, most practitioners believe that
reimbursed expenses can be deductible under Sec. 174.
Practitioners hope that a de minimis rule will permit these
deductions, although there is no statutory basis for this
conclusion.
Pre-contract costs incurred after formation of the partnership can be reimbursed on a deductible basis, as provided for in
the partnership agreement. Pre-contract work may begin, based
on the understanding that the partnership will raise the money to
reimburse these costs.
Regardless of the arrangements for reimbursement of
these costs, the following tax issues must be considered:
•

Do the costs represent true R&D costs or costs to
purchase technology?
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•

Was the work performed on the partnership's behalf and
at its risk?

•

Did pre-contract work produce anything that was
"reduced to practice" before the partnership was finally
organized? 11

In early 1984, legislation was proposed to prohibit a
partner in a cash basis partnership from taking a current
deduction for reimbursement of costs, if those costs were
incurred prior to the partner's admission to the partnership. If this
legislation is enacted, payments made by a partnership would be
allocated to partners based upon when the partners were
admitted to the partnership.
Software
Expenditures

Development

Costs

as

Qualifying

R&D

The IRS has never concluded that software development
costs are R&D costs, but a 1969 ruling states that software
development costs are deductible under rules which are "similar
to" Sec. 174 expenditures. 12 Several recent private letter rulings
treated software development costs as Sec. 174 expenses, while
continuing to refer to them a "similar to" Sec. 174 deductions. 1 3
In 1983, the IRS issued proposed regulations under Sec.
174 which stated that the costs of developing computer software
were not research or experimentation expenditures within the
meaning of Sec. 174 if the operational feasibility of the software
in question were "not seriously in doubt." This proposed
regulation was issued simultaneously with and as a clarification
of the expenditures which qualified for the calculation of the Sec.
44F tax credit for research and experimentation. After the
issuance of these proposed regulations, the IRS announced that
the rules on deductibility as set out in Rev. Proc. 69-21 would not
be superseded by the proposed regulations. 1 4 Consequently,
software development costs that do not meet the criteria of
doubtful operational feasibility do not qualify as R&D
expenditures for purposes of Sec. 44F, but may qualify as R&D
expenditures that are currently deductible under Rev. Proc.
69-21.

11
This "reduced to practice" issue affects both whether the partnership can
deduct the costs under Sec. 174 and whether the partnership can ultimately
realize long-term capital gains under Sec. 1235.
12

Rev. Proc. 69-21, 1969-2 CB 303.

13

See, e.g., IRS Letter Ruling 8136024 (TAM, 5/27/81).

14

Announcement 83-83, 1983-19 IRB 66.
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The Alternative Minimum Tax Problem
Under the Tax Equity and Fiscal Responsibility Act of
1982 (TEFRA), individual investors who elect to currently deduct
research and experimentation expenditures under Sec. 174 must
include 90% of such deductions as tax preference items subject
to the alternative minimum tax. 1 5 Under Sec. 58(i), the preference
item can be avoided by an election to amortize the prepaid R&D
deduction over ten years. However, this strategy would defeat the
tax purpose of the partnership.
The impact of the alternative minimum tax will be dependent on each taxpayer's circumstances. For tax-oriented investors already subject to alternative tax, the net tax benefit from
R&D partnership investments may be negligible (at worse, the investments would generate only a 2% tax deduction). Consequently, the potential returns may not be sufficient to induce
the taxpayer to invest. Each taxpayer must evaluate his or her
own tax position and determine whether, after consideration of
the alternative minimum tax, the investment return is adequate.

Deducting Other R&D Partnership Expenses
Warrants
Under some R&D contract arrangements, the partnership
receives warrants for stock in the sponsoring company, presumably to encourage investment. The IRS will probably try to reclassify a portion of the amount paid under the R&D contract as a
cost to purchase the warrants, rather than as R&D expense. The
value of the warrants will depend upon the maturity of the company and the particular circumstances in each instance. Practitioners should consider this issue at the outset, making apropriate allocations in the documents rather than risking an allocation
by the IRS in a later examination.
Administration Fees
Administration fees paid to the general partner and reimbursement of the general partner's out-of-pocket costs should be
deductible as Sec. 162 deductions, as long as the partnership is
conducting a trade or business. (See the discussion of this "trade
or business" requirement on page 89.)
Organization Costs
Costs incurred for the actual formation of the partnership,
including the drafting of the partnership agreement and the
various filing fees, must be capitalized. However, the costs can
be amortized over 60 months. 1 6
15

TEFRA adds Sec. 57(a)(6) which treats R&D expenditures as a tax preference
item for alternative minimum tax purposes.
Sec. 709(b).
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Syndication Fees
Syndication costs are those incurred in the sale of partnership units, including: the legal, accounting, and consulting
fees related to the offering; the cost of producing the prospectus;
and any commission paid on sale of the units. Fees for advice
pertaining to the adequacy of the tax disclosures in the prospectus are also considered syndication costs. 1 7 Syndication costs
must be capitalized and may not be amortized. 18
Tax Advice
Fees paid for advice on the income tax consequences
from operation of the partnership are deductible under Sec.
212(3) when paid. Expenses incurred in connection with the
realization and monitoring of royalty income, including general
and administrative expenses, are deductible under Sec. 162(5).
Start-up Costs
Start-up costs, which are defined as expenditures for
initial activities before the actual commencement of "business,"
may, at the partnership's election, be amortized over not less
than 60 months from the date business begins. 1 9
The "Trade or Business" Problem
The IRS may contend that many partnership expenses,
otherwise deductible under Sec. 162, should be capitalized
because the partnership is not "carrying on a trade or business."
Although you could argue that the partnership's business begins
when research is started, the IRS approach has been to deny the
"carrying on a trade or business" status until income has been
realized or some product offered for sale. 2 0
Complicating matters, the House Committee Report to
Sec. 221 of ERTA regarding the research and experimentation
credit states, "Receipt of royalties does not constitute a trade or
business under present l a w . . . . In such a case, the nexus
between the research and the transferee's activities generally
would be insufficient to support a finding that the taxpayer had

17

Prop. Regs. Sec. 1.709-2(b).
Sec. 709(a).

19 Sec. 195(a).
20 Rev. Rul. 81-150, 1981-1 CB 119.
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incurred the research expenditures in carrying on a trade or
b u s i n e s s . " 2 1 Under this rationale, a typical royalty R&D
partnership may never be viewed as carrying on a trade or
business, and an equity partnership may not be viewed as
carrying on a trade or business until it begins to realize income or
ships the product. (The report goes on to say that "under
appropriate circumstances, nevertheless, the nexus might be
deemed adequate for purposes of the Sec. 174 deduction.")
Some practitioners recommend that the sponsoring
company or a partner or joint venturer transfer some product to
the partnership so that the partnership qualifies as "carrying on a
trade or business" from the outset. The problem is also avoided
when a joint venture is formed with the sponsoring company to
manufacture and market the product.
If the IRS successfully argues that an R&D partnership's
non-R&D expenses cannot be deducted as Sec. 162 expenses because of the trade or business requirement, these expenditures
could probably be treated as start-up costs to be capitalized and
amortized over 60 months from the date business begins. If startup costs are to be amortized, the partnership must make an
election to do so at the time its first tax return is filed.

Sale Of The Technology
One of the goals of many R&D partnerships is to enable
the investors to recognize the ultimate sale of the technology as
long-term capital gains. Various techniques enable the partnership to do this.
Section 1235
The sponsoring company will usually want to buy the
completed technology as soon as it has been developed, as the
company generally wants to control the technology as soon as it
can do so. Sec. 1235 permits the transfer of the technology to the
sponsoring company with any gains treated as long-term capital
gains, even if the partnership has only held that completed technology for a short period. This long-term capital gains treatment
is automatic, as Sec. 1235 confers capital asset status with no
holding-period requirements. In addition, the entire gain is
treated as long-term capital gain even when the consideration is
payable over time (e.g., as in the instance of royalties), thus avoiding the imputed interest rules of Sec. 483. (Sec. 483 is discussed
on page 97.)

21

House Committee Report on H.R. 4242, 97 t h Cong., 1st Sess. (1981).
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Although Sec. 1235 is often thought to confer a tax
benefit on patented technology, it also applies to technology that
is patentable. There is no need for an actual patent or even an
application. 2 2 This is a critical consideration for many high technology companies, which are often unwilling to make the public
disclosures required to obtain a patent.
To qualify for capital gains treatment under Sec. 1235,
there must be a transfer of "all substantial rights." The provision
will not apply to a sale of patentable technology rights by the
partnership if the rights sold are limited geographically (e.g.,
within the country of origin) or in duration (e.g., to a period less
than the remaining life of the patent or useful life of the underlying technology). Similarly, Sec. 1235 will not apply if the sponsoring company (or anyone else) purchases the technology from the
partnership under an agreement that (1) limits the company to
less than all the claims and inventions covered by the patent, or
(2) limits the use of the patent or patentable technology to fields
of use within specified trades or industries covering less than all
the existing and valuable rights. 2 3 In addition, the transfer of
rights must include the right to use, make and sell the patented
or patentable article or device. 2 4
In summary, to satisfy the "all substantial rights" test,
the agreement transferring the technology should provide for the
transfer of all rights to use, manufacture, and sell the product or
products throughout the world during the period of the
technology's useful life, and the ability to prevent disclosures,
including any disclosures by the R&D partnership itself, of the
technology to unauthorized persons.
The partnership may want to retain a security interest in
the transferred technology to protect itself against the sponsoring company's failure to pay royalties or to make note payments.
This will not invalidate the use of Sec. 1235, as a security interest
is not viewed as a substantial right for this purpose. 2 5
In many situations, the developed technology may be
22

Regs. Sec. 1.1235-2(a) suggests that the technology can be patentable for Sec.
1235 to apply, since a patent or patent application need not exist. See Max A.
Burde, 352 F2d 995 (2d Cir. 1965) (16 AFTR2d 5885, 65-2 USTC para. 9733), cert.
denied 383 US 966 (1966); F.H. Philbrick, 27 TC 346 (1956).
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Regs. Sec. 1.1235-2(b).

24

Taylor-Winfield Corp., 476 F2d 483 (6th Cir. 1972) (30 AFTR2d 72-5711, 73-1
USTC para. 9113).
25

Regs. Sec. 1.1235-2(b)(2)(ii).
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partly patentable and partly nonpatentable. For example, a computer may be patentable, but the software that allows it to
operate is not. When the sales contract does not include an
allocation, the IRS will attempt to allocate some consideration to
nonpatentable technology to disallow Sec. 1235 treatment for
that portion of the sale. Contracts should therefore allocate the
purchase price between patentable and nonpatentable
technology. The patentable technology can be sold immediately,
resulting in long-term capital gains treatment under Sec. 1235.
The nonpatentable technology can be licensed to the sponsoring
company and sold when the holding-period requirements have
been satisfied.
In addition to the "all substantial rights" requirement,
Sec. 1235 applies only to sales of patentable technology by a
"holder." Sec. 1235 defines a holder as an individual who created
the technology or acquired an interest in the technology from the
creator in exchange for consideration paid in money or money's
worth. 2 6
A corporation is not an "individual," and therefore cannot
qualify as a "holder." Similarly, an R&D partnership does not
qualify as a "holder"; however, the regulations apply a "look
through" approach, and allow individual partners to qualify for
Sec. 1235 treatment 2 7 Corporate partners in an R&D partnership
do not qualify.
Under the definition of "holder," the individual partners of
the R&D partnership will qualify for capital gains treatment only if
the partnership acquires the patentable property from the creator
for consideration in money or money's worth. Usually, the R&D
partnership will give the creator a partnership interest in exchange for the base technology, and this interest constitutes
"money's worth." Alternatively, the partnership may make a direct payment of a fixed sum to the creator or provide the creator
with property to use in developing the technology. 2 8 Where the
creator is not a partner, some practitioners recommend that each
partner (rather than the partnership) pay something directly to the
creator. Regardless of the approach selected, the payment for
the purchase of base technology cannot be deducted by the
partnership.

26 Sec. 1235(b).
27 Regs. Sec. 1.1235-2(d)(2).
28 Regs. Sec. 1.1235-2(d)(2).
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The base technology will often be developed by an employee of a corporation. The corporate employer of the inventor at
the time the technology is transferred to the partnership does not
qualify as a "holder." 2 9 Frequently, however, the employee will
have given up all rights to the invention under his or her employment contract. In order to give the R&D partnership an opportunity to use Sec. 1235 in this situation, the corporate employer
must release the creator from any obligations under the employment contract and transfer any rights in the base technology
back to the creator. The creator can then assign his or her patent
rights to the partnership in exchange for money or money's
worth.
Partners also cannot qualify if they are related to the
creator/inventor. A related person for purposes of Sec. 1235 is a
family member, such as a grandparent, parent or child. However,
brothers or sisters don't count as family members for this
purpose. 3 0
Additionally, the partner cannot qualify if the partnership
sells the technology to a "related" corporation. The partner and
partnership will not be considered related to the corporation so
long as they do not own, directly or indirectly, 25% or more of the
corporation's stock. For this purpose, stock owned by a partnership is considered to be owned proportionately by its partners,
and any partner owning stock in a corporation is deemed to
also own the stock owned by the other partners. Accordingly, the
related corporation rule should not create a problem as long as
all partners in the R&D partnership own less than 25% of the
sponsoring company. However, if partners, in the aggregate, own
more than 25% of the company, all partners owning any stock in
the sponsoring company will be disqualified as "holders" because they will be treated as related to the company, as will the
inventor/creator if that person is also a partner.
If the R&D partnership itself has a stock interest in the
sponsoring company, the partners will be viewed as owning what
the partnership owns for purposes of the 25% test. In most R&D
partnership arrangements the R&D partnership does not own any
stock in the company. However, R&D partnerships and/or partners do sometimes receive warrants in the company. It is not
clear whether these warrants constitute a stock interest which
could disqualify the partners as "holders."
R&D partnerships sometimes need a second infusion of
capital from new and different partners to fund the completion of
the R&D work. Careful planning may be necessary so that these
29

Sec. 1235(b)(2)(A).

30

Regs. Sec. 1.1235-2(f)(1).
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new partners can also qualify as "holders." For purposes of Sec.
1235, the original partners acquired the base technology from the
creator, but the new partners must also acquire the technology
from the creator to qualify under that provision. One solution is to
hold open the assignment of the inventor/creator's rights, and
have each new partner make some payment directly to the
inventor/creator. 31 The problem can be avoided, however, if the
inventor/creator is named the general partner in the R&D partnership. With this approach, when the new limited partners
purchase their interests in the partnership, those interests are
considered to be purchased from the creator/general partner.
Sections 1221-1223 and Section 1231
Because of the stringent requirements of Sec. 1235, many
R&D partnerships must rely on other sections of the Code to obtain long-term capital gains treatment on sale of the developed
technology to the sponsoring company. Sections 1221-1223
(which deal with the sale of capital assets) and Sec. 1231 (which
deals with the sale of property used in a trade or business) may
provide the bases for this treatment.
A capital asset is defined in Sec. 1221 as property which
is (1) not held for sale to customers and (2) not used in a trade or
business and subject to depreciation. Depreciable or amortizable
property used in a trade or business that has been held for more
than one year after reduction to practice can qualify for capital
gains treatment under Sec. 1231. Copyrights, letters, memoranda
or similar property created by the taxpayer are ineligible for
capital gains treatment under either Secs. 1221 or 1231.
Reliance on Secs. 1221 or 1231 for capital gains treatment
involves three main issues: (1) whether a sale or exchange has
occurred; (2) whether the developed technology qualifies as a
capital asset (or property); and (3) whether the technology has
been held long enough by the partnership to qualify for long-term
capital gains treatment upon sale to the sponsoring company.
Occurrence of a sale or exchange. A base technology
transfer agreement provides the partnership with the right to use
the sponsoring company's technology within a specified field
and territory. Occasionally (most often with established
companies), the agreement will also provide that any partnershipdeveloped technology may be used by the sponsoring company
outside the specific territory and field of use. This provision
assists in sustaining that the original transfer of technology
should be a royalty-free license without any recharacterization of
31

See, e.g., Donald, 228-2d T.M., Patent Transfers - Sec. 1235, at 4-7.
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the development fees as payment for previously developed
technology. It also allows the sponsoring company to use
portions of the technology for other products which are not being
funded by the partnership.
Under such an agreement, however, the IRS might argue
that, although the partnership transferred all of the rights which it
had in the technology at the time it sold the technology to the
company, the partnership may not be selling all of the substantial
rights which it ever had in the property. If this argument could be
sustained, then the payments received for the technology would
be ordinary income as there would be no sale or exchange.

Qualifying as a capital asset. In considering whether the
technology is a capital asset, two subsidiary issues may be
involved: the tax benefit rule and the exclusion of inventory from
the definition of capital assets.
In 1984, the IRS, in a technical advice memorandum 3 2 ,
applied the tax benefit rule to determine that a company was
required to recognize the proceeds from the sale of patents and
secret technology as ordinary income to the extent that
expenditures attributable to the development of the property
were taken as an ordinary deduction under Section 174(a). Citing
the Hillsboro National Bank case 3 3 as authority, the IRS
contended that to classify the gain on a subsequent sale of
technology as solely capital gain was fundamentally inconsistent
with the earlier development deductions. Thus, only the gain in
excess of the 174(a) expenses could be eligible for capital gains
rates. Although expectations are that the IRS position will
ultimately be challenged and final determination made in the
courts, practitioners should be aware that the IRS will attempt to
use the tax benefit rule to classify a portion of the sale proceeds
as ordinary income. Selling the partnership interests (which is
discussed on page 99) may be one alternative for avoiding the tax
benefit rule issue.
The more difficult problem in achieving capital asset
status for the technology stems from the Sec. 1221 definition of
capital assets. Inventory is excluded from this definition, and,
therefore, the sale of inventory produces ordinary income regardless of the holding period. R&D partnerships may have difficulty
in establishing that the technology is not inventory. Since the
partnership may never be in a position to manufacture, market,
and sell a product, the IRS may view the sale of the technology
32 IRS Letter Ruling 8409009.
33 Hillsboro National Bank, 130 US 1134 (1983) (51 AFTR2d 83-874, 83-1 USTC para
9229).
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itself as a foregone conclusion. Further, if the sponsoring company has an option "up front" to purchase the technology as part
of the R&D contract, the contention that the technology is inventory seems stronger.
The partnership may be more successful in establishing
that the technology is a capital asset if it can characterize the
partnership as a product-oriented rather than a technologyoriented organization. The partnership can argue that it must rely
on sales of the ultimate product rather than the sale of the technology for its revenue. A royalty arrangement based on sales
would bolster this argument more effectively than either a lumpsum payment for the purchase or a requirement for substantial
minimum royalties, since the royalty arrangement suggests that
the R&D partnership is product-oriented.
To meet the holding period requirements discussed below, the partnership must license the technology to the sponsoring company before the sale. By closely monitoring the product
during the license period, the partnership may strengthen its
claim to being a product-oriented venture. Although it is generally impractical to do so (especially in high technology), the partnership may want to license the technology to more than one
licensee until the technology is sold.
The use of a joint venture arrangement with the
sponsoring company to manufacture and market the product
strengthens significantly the partnership's argument that it is a
product-oriented venture. This is because the partnership must
rely on net income from joint venture operations rather than sales
by the sponsoring company.
The type of purchase option given the sponsoring
company is a critical factor in determining whether the
technology is inventory. The option must be a true option, with
the real possibility that the company may not exercise it. If the
terms of the arrangement, the surrounding circumstances, or
good business practice can compel the exercise of the option,
the likelihood of capital asset treatment will be reduced. Most
partnerships require an upfront nonrefundable cash payment
upon the exercise of the purchase option.
Holding period. If the technology qualifies as a capital
asset, the partnership must demonstrate that it has met the
twelve-month holding period when the technology is sold. The
partnership's holding period starts when the technology has
been "reduced to practice." Therefore, the technology must be
leased or licensed to the user, or a joint venture must be
established, for a period equal to the required long-term holding
period. The lease or license period should actually be longer than
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the required holding period because of uncertainty as to when
the technology has been "reduced to practice." The best
approach is to obtain a patent counsel's opinion on when the
technology has been reduced to practice and then license or joint
venture it for 14 to 16 months thereafter.
Any option to acquire the technology granted by the
partnership should not be exercisable until the license or joint
venture period has expired. The option should again be a true
option; otherwise the IRS may treat the arrangement as an
installment sale. The Supreme Court has held that when property
is leased or licensed, the property is deemed sold when the
option is exercised, rather than when the lease or license is
entered into. 3 4 However, if the lease or license arrangement is
essentially an installment sale contract, the technology will be
deemed sold when the contract is made. 3 5 For the R&D
partnership, this would mean a sale without a sufficient holding
period.
To create the strongest case for true license or joint
venture treatment, the partnership should follow the basic rules
for operating leases. License fees or joint venture income should
not be applied to the option price. If a license is used, it should be
non-exclusive to avoid an argument that substantially all rights
had been transferred when the license agreement was signed.
The partnership must remain at risk during the license or joint
venture term, with no guarantee that anyone will exercise the
option to acquire the technology. Finally, the partnership should
not have a right to "put" the technology to anyone at the close of
the license period.
In order to qualify as a capital gains asset under Sec. 1221
or 1231, the technology must be "property." Patents, patent
applications, and some copyrights are considered property, but
trade secrets will be considered property only if they are truly
secret, create some competitive advantage, and are legally
protected against unauthorized disclosure and use. Know-how
must meet the same requirements as trade secrets or be ancillary
to patents, applications, or trade secrets. If development is
subcontracted out to others or if information is divulged in
articles or speeches, then the trade secrets or know-how may not
be truly secret and therefore not qualify as property. For purposes
of a patent sale, the sale of the "property" must, to satisfy Sec.
1221, include all substantial rights, geographic and field of use.

34 San Joaquin Fruit & Investment Co., 297 US 496 (1936) (17 AFTR 470, 36-1 USTC
para. 9144).
35 Karl R. Martin, 44 TC 731 (1965).
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Computer software is generally protected by copyright. If
the software is created by the taxpayer (i.e., the partnership),the
copyright is ineligible for capital gains treatment. If the software
is developed by either the sponsoring company or a third party for
an arms-length price, it should qualify as property and be eligible
for capital gains treatment under Sec. 1231.
Sec. 483. Sec. 483 of the Code provides that interest be
imputed on deferred payments made under contracts for the sale
of property. Since R&D royalty agreements are essentially sale
contracts calling for long-term payments, a portion of each
royalty payment is usually characterized as interest and is
taxable as ordinary income.
Sec. 1239. The sale of the technology may also raise
issues under Sec. 1239, which disallows capital gains treatment
on sales of depreciable property to related parties. Since patents
(and, under some decisions, patent applications) are depreciable
property, a sale of patented technology by the partnership to a
related entity will result in ordinary income. For purposes of Sec.
1239, a related entity is one in which the partnership or its
partners own more than 80%. The Sec. 318 attribution rules apply
in determining whether the partners and partnership own 80% or
more of the sponsoring company.
The sale of unpatented technology or secret formulae to
related parties would probably not result in ordinary income treatment under Sec. 1239, because these assets have an indeterminate useful life and are therefore not depreciable. 36 When the
R&D partnership sells the technology to a domestic corporation,
it can realize long-term capital gains. The corporation can then
patent the technology and amortize its cost over the patent's life
or a shorter period.
Sec. 351. When the partnership owns 80% of the
sponsoring company, the sale of unpatented technology must be
carefully planned to prevent the transaction from being treated as
a contribution to capital under Sec. 351. If the IRS views the sale
as a contribution to capital, royalties later paid to the partnership
would be treated as dividends — non-deductible to the
corporation and ordinary income to the partners.
Sec. 1249. Under Sec. 1249, income from the sale of a
patent, invention, model or design by an R&D partnership to a
controlled foreign corporation (generally, more than 50% owned,
using Sec. 958 attribution rules) will be treated as ordinary
income rather than capital gains.
36 See, e.g., Lan Jen Chu, 486 F2d 696 (1st Cir. 1973) (32 AFTR2d 73-6022, 73-2
USTC para. 9750), aff'g 58 TC 598 (1972), acq. 1978-2 CB 1; Est. of William F. Stahl,
422 F2d 324 (7th Cir. 1971) (27 AFTR2d 71-1077, 71-1 USTC para. 9322), aff'g in
part and rev'g in part 52 TC 591 (1969), nonacq. 1978-2 CB 4; Bette C. Graham, N.D.
Tex 1979 (43 AFTR2d 79-1013, 79-1 USTC para. 9274).
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Sale of Partnership Interests
When the sale of partnership assets does not qualify for
capital gains treatment under Sec. 1235, the most frequently
used alternative is the sale of the partnership interests rather
than the technology. This approach avoids many of the problems
previously discussed as long as the sale of the partnership interests cannot be recharacterized as a sale of assets. The holding
period for the partnership interest starts when the investment is
made, rather than when the technology is "reduced to practice."
In addition, the partnership interest clearly constitutes a capital
asset. 37 There are no questions as to whether a sale or exchange
occurred, whether the technology is property, nor whether the tax
benefit rule may be applicable.
Under Sec. 751, however, any proceeds from the sale of
partnership interests attributable to unrealized receivables or
substantially appreciated inventory of the partnership will be
taxed as ordinary income. Generally, the partnership will have unrealized receivables only to the extent of license agreement fees
or unrecognized income in a joint venture.
Generally, the costs of the technology will have been deducted as R&D expense, giving the partnership a zero tax basis
for the technology. If the IRS treats the technology as inventory,
then it will be "substantially appreciated inventory" within the
meaning of Sec. 751. Consequently, the same issues with Secs.
1221-23 and 1231 regarding inventory are also issues in the sale
of partnership interests. While the holding period for partnership
interests start when the investment is made, the partnership may
still need to hold the technology for twelve months after it is reduced to practice before the partnership interests are sold.
The Equity Partnership
For early-stage companies, the most popular R&D partnership arrangement is the "equity partnership." Under these
arrangements, the partnership interests are converted to stock
interests at a later date. By starting as a partnership, a company
can pass through its early losses from expended R&D to the
partners. The partnership can then incorporate or merge with a
corporate entity and the partners can exchange their partnership
interests for stock in the corporation. These stock interests can
be sold when the company goes public or becomes involved in a
major sale of the company's stock. Sale of the stock by the
partners/stockholders results in capital gains.
This approach to the realization of capital gains avoids
many of the technical difficulties that may arise under either Sec.
1235 or Sec. 1221. The incorporation should be tax-free under
Sec. 351.
37

See Sec. 741.
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When the sponsoring company gets stock in the new corporation, however, the sponsoring company may appear to have
received equity with a value greater than the property it transferred. This "property" often consists of little more than a
promise to provide the know-how and other skills necessary to
manufacture and market the product. If these items are not
considered "property" for purposes of Sec. 351, the company
may recognize ordinary income on receipt of the stock. If the
company receives more than 20% of the new corporation and
does not transfer "property" to the new corporation, the
incorporating transaction would be taxable to the partnership. To
achieve tax-free treatment under Sec. 351, the company should
transfer prototypes, cash, or equipment along with expertise, in
exchange for the stock interest.
Because this incorporation technique yields a tax-deductible equity investment in a corporation not achievable by buying
stock in the corporation at the outset, it appeals to venture capital investors. The IRS may argue that the partnership should be
disregarded because it lacks any real economic reason or substance. In many cases, the founding partners may be unable to
demonstrate any business purpose for the interim use of a partnership other than providing the investors with a deductible
equity interest in a corporation. To avoid this problem, equity
partnerships should be designed so that the incorporation of the
partnership does not serve as an integral part of the overall plan
from the outset. Some recent equity partnerships provide that incorporation of the partnership requires an affirmative vote by the
general partner and a "super majority" (2/3) of the limited
partners. This provision may introduce sufficient uncertainty as
to whether incorporation will, in fact, take place.
Lump-Sum Buy-Outs
Under many R&D contracts, the sponsoring company has
an option to buy the technology from the partnership for a lump
sum, payable in cash or in stock of the sponsoring company.
Even if the lump-sum sale is structured as a capital gains transaction, a lump-sum buy-out for stock may leave the partners with no
cash to pay the capital gains tax. Accordingly, the partnership
can often choose a combination cash-and-stock payment when
the sponsoring company exercises its option to buy the technology for a lump sum.
A tax-free stock buy-out may be structured, however,
using provisions of Sec. 351. To do this, the sponsoring company
organizes a subsidiary after the technology is developed. The
company transfers to the subsidiary the prototypes, cash, and
other assets necessary to manufacture and market the product in
exchange for 80% of the stock. Simultaneously, the partnership
transfers its technology to the subsidiary in exchange for the
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other 20% of the stock. By qualifying these transactions under
Sec. 351, the partnership does not recognize gain from the
receipt of the stock. To protect the partnership, the partners
should be given a "put" option, allowing the partnership to put its
stock interest to the parent corporation in exchange for parent
company stock in the event of a public offering or other major
sale of the parent company's stock. Careful drafting of the put
will be necessary so that the put does not disqualify the transaction under Sec. 351. It may also be necessary to give the parent
company a call option on the partners' stock, so that the company can protect its interest and consolidate the subsidiary's
earnings for financial statement purposes.
Availability of

Research and Experimentation

(R&E)

Credits
The Committee Reports on ERTA indicate that royalty
R&D partnerships are not eligible for the R&E tax credit under
Sec. 44F. The mere receipt of royalties cannot be viewed as carrying on a trade or business, which is required by Sec. 44F(b)(1).
Whether the credit is available to equity partnerships is
less clear. The IRS will probably argue that the equity partnership
is not carrying on a trade or business until it has revenues or
ships a product. Even if the equity partnership is considered to be
carrying on a trade or business, Sec. 44F provides that the credits
passed through to the partners can only be used to offset any tax
liability stemming from taxable income from the equity partnership. In most cases, this will mean carrying the credit over to
some future date when the partnership has net income; the
present value of the credit may, therefore, be of little benefit.
Legislation has been proposed to extend the credit to
start-up corporations and corporate joint ventures. Start-up R&D
partnerships will probably still be excluded.
Even in the few cases in which an R&E credit might be
available, R&D partnerships must adhere to special rules on
prepaid contract R&D. Where the R&D has been prepaid, only the
portion of prepaid expenses allocable to the research performed
during the year may be included in determining the amount of the
credit.
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APPENDIX II
TAX CONSIDERATIONS FOR
THE SPONSORING COMPANY
For the sponsoring company in an R&D partnership, the
tax consequences are fairly straightforward. The company
should be aware of the taxation of R&D contract revenue, the
deductibility of royalty payments, and the potential reallocations
under Sec. 482 of the Code.

Taxable Income
Unlike the debt or equity funds that a company receives
to conduct research, funds received from an R&D partnership are
taxable. Since the partnership often prepays the R&D contract
with no restrictions, the company that is not careful could wind
up using a substantial part of the proceeds to pay taxes, rather
than to conduct research.
The IRS has generally taken the position that prepaid
revenue is taxable in the year of receipt. If the IRS requires a
sponsoring R&D company to recognize prepaid R&D contract income in the year of receipt, it would seem equitable to allow the
estimated R&D costs for the project to be offset against the
prepaid revenue. Although some appellate courts have accepted
this reasoning, the Tax Court has never agreed. 1
A sponsoring company should try to defer the inclusion
of the R&D contract revenue as taxable income until the deductions for the research and development are available to offset the
income. The two most commonly employed techniques to
achieve deferral are the completed contract method and the
Revenue Procedure 71-21 2 method.

1
E.W. Schuessler, 20 F2d 722 (5th Cir. 1956) (49 AFTR 322, 56-1 USTC para. 9368),
rev'g 24 TC 247 (1955); Pacific Grape Products Co., 219 F2d 862 (9th Cir. 1955) (47
AFTR 214, 55-1 USTC para. 9247), rev'g and rem'g 17 TC 1097 (1952).

2 Rev. Proc. 71-21, 1971-2 CB 549.
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Completed Contract Method
Under the completed contract method, the company
reports the income and deducts costs allocable to the contract in
the year the contract is completed (when final completion and acceptance have occurred). To use this method, Regs. Sec.
1.451-3(a) requires a long-term contract, generally more than 12
months. Many R&D contracts may not fall within the definition of
a long-term contract, however, because Regs. Sec. 1.451-3(b)(1)(i)
defines this term as "a building, installation, construction, or
manufacturing contract which is not completed within the
taxable year in which it is entered into." Since many R&D
contracts are really viewed by the parties as service contracts,
the definition may prevent the use of the completed contract
method. For example, when an architect was basically providing
services rather than constructing a building, he was not
permitted to use the completed contract method to recognize his
revenues on the contract. 3 Similarly, an engineer was not allowed
to use the method for engineering services he was providing
because the services were not under a long-term contract, and he
was not required to construct or build anything. 4
To minimize this problem, R&D contracts should provide
as much support as possible for using the completed contract
method. The contracts should specifically require the company
to build a working prototype, or some other tangible product,
from the R&D work and to deliver it to the partnership. Since the
prototype would then be owned by the partnership, the partnership might lose some R&D deductions for the costs necessary to
build it. These lost deductions may not be too significant, however, when compared to the benefits the sponsoring company
would realize from using the completed contract method.
Revenue Procedure 71-21
The definitional problems of the completed contract
method can be avoided when Rev. Proc. 71-21 is used. Under Rev.
Proc. 71-21, the inclusion of prepaid R&D in income can be deferred until the actual R&D work is performed, but in no event
beyond the end of the year following the year of receipt. To rely
on the revenue procedure, the R&D contract must specify that all
R&D is to be performed before the end of the year following the
taxable year of receipt.

3

Rev. Rul. 70-67, 1970-1 CB 117.

4

Rev. Rul. 80-18, 1980-1 CB 103.
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The actual amount of income deferred is determined
according to the portion of the R&D contract unperformed at the
end of the year of receipt. For example, assume the R&D partnership prepays $2 million to a calendar-year accrual basis company
in November 1983, pursuant to a one-year contract. On December
31, 1983, 75% of the R&D work remains unperformed. Under Rev.
Proc. 71-21, $500,000 of income is recognized in 1983, while $1.5
million of income would be recognized in 1984, regardless of
whether the contract is completed by December 1984.
A newly-formed sponsoring company can maximize the
deferral available under Rev. Proc. 71-21 by electing a tax year
which ends just before the first prepayment is received. In this
way, the company can defer recognition of a portion of the income for almost two full years.
The sponsoring company must maintain books and
records to substantiate the amount deferred at year-end. In addition, the amount included in taxable income must conform to the
amount included in book income, or the income reported by the
company to shareholders or to others for credit purposes.

Deductibility of Royalty Payments
When the sponsoring company purchases developed
technology from the partnership, it generally expects the useful
life of that technology to extend well beyond a year. Under conventional tax accounting principles, the cost of the technology
should be capitalized and deducted over the useful life of the
technology.
When the company acquires the technology in exchange
for a royalty based on sales, the total cost must still, theoretically, be capitalized; however, the total amount may not be determinable. In Associated Patentees, Inc., 5 the Tax Court held that
since the total royalties that would ultimately be paid
represented the total cost of the technology, the actual royalties
paid during any particular period was the best indication of the
utility (or depreciation) of that asset during the period. Thus, the
Court permitted royalty payments to be deducted as paid or
incurred for the period involved.
In situations where a "cap" exists on the royalties and
appears to be attainable before the end of the patent's useful life,
the IRS may argue that the royalties paid are not a reasonable

5

Associated Patentees, Inc., 4 TC 979 (1945), acq. 1959-2 CB 3.
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measure of the amortization. For instance, if sales projections indicate that the cap will be reached within four years, the IRS may
argue for capitalizing the expected cumulative royalties and
amortizing that total over the patent's statutory life of seventeen
years. Similarly, if a company must pay excess royalties to reach
a minimum royalty level, the IRS may argue that the excess
amounts should be capitalized. Both of these arguments may be
difficult to sustain, however, in view of the uncertainty of future
sales and the real useful lives of patents.

Allocation of Income and Deductions
Under Sec. 482, the IRS has the authority to allocate income and deductions between or among entities under common
control if such allocation will more clearly reflect the income of
any of the entities. In the case of an R&D partnership arrangement, the IRS may attempt to allocate the partnership's R&D
deduction to the sponsoring company or to deny the deduction
entirely, based on a number of theories.
If the overall arrangement is viewed as little more than an
elaborate financing scheme rather than a genuine contract
research project, the IRS may recharacterize the prepaid R&D as
a loan, eliminating both the partnership's deduction and the
company's income. Alternatively, since the partnership will
usually not be able to manufacture or market the product
resulting from the developed technology, the IRS may contend
that the arrangement is actually a joint venture between the
partnership and the sponsoring company, and recharacterize the
prepaid R&D as a nondeductible capital contribution to the joint
venture. In two recent c a s e s 6 the partnerships were
recharacterized as financing transactions based upon certain
factors in the arrangement. These factors included a legal
obligation of the partnership to sell the developed technology, a
general partner that provided no significant services other than
raising capital, and a project where the partnership provided less
than half the necessary development funds in an economic
structure that resembled a loan.
Overpriced research may also create problems. TEFRA
added Sec. 6700, which imposes a penalty for "gross overvaluations" in connection with tax shelters. Overvaluations of the research may also lead to reallocations under Sec. 482 — the R&D
deduction by the partnership would be disallowed to the extent
of the overvaluation, since the payment exceeds the amounts actually required to research and develop the technology.
6

Estate of Helliwell v. Commissioner, 77 TC 1964 (1981) and Broyles v.
Commissioner, 44 TCM 908 (1982).
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These problems can be avoided, to some extent, if all contract arrangements between the partnership and the sponsoring
company suggest arm's-length dealings. In addition, any profit
realized by the sponsoring company from the R&D contract
should be reasonable. The use of an unrelated or independent
party as the general partner should also reduce the likelihood of
reallocations. If the sponsoring company serves as general
partner, the company may argue that its fiduciary responsibilities
to the limited partners prevent it from exercising too much control on behalf of the company. Because the sponsoring company
effectively controls both entities, however, the IRS is more likely
to argue for reallocations.
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APPENDIX III
ACCOUNTING IMPLICATIONS
The emergence of R&D partnerships in the late 1970s was
accompanied by an increased number of SEC filings for sponsoring companies. The SEC became aware that the companies receiving funds from R&D partnerships were accounting for these
funds in many different ways. In response, the SEC took the position that, in the absence of evidence to the contrary, these transactions were only alternative financing techniques, not true
contract research for another entity who bore the risk of unsuccessful development. Consequently, the SEC indicated that
these transactions should be accounted for as forms of debt. Although the SEC may not have viewed this approach as suitable in
all cases, the Commission's position forced the accounting
profession to address the issue. At the same time, R&D partnership activity quickly decreased, since the availability of so-called
"off-balance sheet" financing, one of its major attractions, was
virtually eliminated for public companies.
In April 1982, the Financial Accounting Standards Board
(FASB) issued an Exposure Draft entitled "Research and Development Arrangements." After considering letters of comment in
response to this Exposure Draft, the FASB issued Statement of
Financial Accounting Standards No. 68 - Research and Development Arrangements (SFAS 68) in October 1982.
SFAS 68 indicates that when research is funded by
others, there may be an obligation, either contractually or
otherwise, for repayment of such funding regardless of the
project's success. In such circumstances, if the arrangement is,
in substance, a financing technique, the sponsoring company
must recognize its liability under the agreement in its financial
statements in a manner similar to any commercial loan financing.
But, if the overall arrangement is determined to be a contract to
perform research for others, it should be accounted for
accordingly.
Some judgement must be used in determining whether
the arrangement is a contract to perform research for others. The
sponsoring company must determine the substantive nature of
its obligation when it contracts with other parties who fund the
research. If the company is obligated to repay (or if, based on
surrounding circumstances, it is probable that the company will
repay) some of the funds provided, even if the research is unsuccessful, then the company must account for this obligation as a
liability.
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If the sponsoring company has no liability, contractual or
otherwise, because repayment is contingent solely upon the
results of the project, and there is sufficient uncertainty as to the
project's success, the company should account for the arrangement as a contract to perform R&D activities for others. To adopt
this position, however, the economic success of the R&D cannot
be guaranteed by the company, and the company cannot be obligated to make any future payments or issue securities to the R&D
partnership (which is sometimes true of equity partnerships).
Determining the proper accounting treatment will be
most difficult when there is no contractual obligation to repay the
partnership or to acquire the partnership's technology, but it appears likely that the sponsoring company has an intent to purchase the results of the research project, even if it proves
unsuccessful. SFAS 68 provides some examples of conditions
that lead to the presumption that the sponsor will repay funds
provided, including when the sponsor: (1) may want to maintain
the ability to enter into another arrangement with the same parties or similar arrangements with other parties; (2) may be forced
to reacquire the base technology to continue conducting its
other activities or to prevent disclosure of the technology to
others by the partnership; or (3) may purchase the results to fulfill
a perceived moral obligation. Similarly, a sponsoring company
may be the general partner and, because of a conflict of interest,
may feel compelled to exercise an option to buy the technology.
Even though written agreements or contracts may not require
repayment of the R&D funds received, surrounding conditions
might indicate that the sponsor is likely to bear the risk of failure
of the R&D effort. Accordingly, the individual facts and circumstances of each situation must be evaluated.
To persuade potential investors, companies sometimes
describe the R&D project as "Big D" (development) and "Little R"
(research) to suggest a lower degree of risk. SFAS 68 states that if
the sponsoring company has essentially completed the project
before entering into the arrangement with the R&D partnership,
there is a presumption that the company will buy out the partnership. Applying the phrase "essentially completed" to high technology contracts may be very difficult for accountants who lack
substantial engineering or other technological knowledge.
In those situations where the sponsoring company serves
as the general partner and contributes cash to the partnership,
the problem of accounting for that investment must be addressed. In an arrangement that has been determined to be a contract to perform research for others under the provisions of SFAS
68, the equity method generally should be used, with the investment reduced as the partnership incurs development expense. In
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certain situations where the sponsoring company is able to control the financial and operating policies of the partnership, consolidation of the partnership with the sponsoring company may
be appropriate. Control of the partnership may exist even if the
general partner has an interest of less than 50%.
SFAS 68 does not address the accounting treatment for
buy-out arrangements of the successfully developed project. The
appropriate treatment involves an assessment of the specific
facts in each situation. The arrangement may contemplate that
the sponsor will eventually acquire the successfully developed
technology for cash, stock or a combination of cash and stock.
An acquisition for cash may result in the sponsor recording an
asset and amortizing that asset over the future periods benefited.
However, there are numerous accounting issues that should be
considered. One such issue involves R&D arrangements that
permit the partnership to receive payment from the sponsor for
the successfully developed project in the form of sponsor
company's stock. The FASB, in Technical Bulletin 84-1 (dated
March 15,1984), states that a company which acquires the results
of an R&D arrangement in exchange for stock should record the
stock at (1) the stock's fair value as of the date the company
exercises its right to acquire the technology or (2) the fair value of
the technology, whichever is more clearly evident. The fair value
of the stock will normally be more clearly evident. In those
situations where the value of the sponsoring company's stock
has appreciated such that the stock value far exceeds the
alternative cash amount, this treatment may result in the
recording of an asset much larger than originally contemplated.
The large asset may raise a further question as to whether the
recorded amount will be recoverable.
Other complexities are introduced when the purchase of
the developed technology by the sponsor is negotiated before
the development is successfully completed. In this regard, GAAP
precludes capitalization of the costs of services performed by
others in connection with the research and development
activities of the sponsor, including research and development
conducted by others on behalf of the sponsor. However, the
costs of intangibles that are purchased from others for use in
research and development activities and that have alternative
future uses (in research and development projects or otherwise)
are capitalizable costs.
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Most partnership arrangements are set up with the tax implications firmly in mind. Because the requirements of SFAS 68
are similar to the tax requirements for contract treatment, the
sponsoring company may be able to account for the R&D partnership arrangement as a research contract if, for tax purposes, such
an arrangement qualified to be treated as a contract to perform
R&D for others.
Another accounting issue arises when the sponsor lends
additional funds to the partnership to complete the project. The
appropriate accounting treatment will depend on the repayment
terms. In most situations, repayment is contingent on successful
development (e.g., the amount loaned is offset against future
royalties payable to the partnership), and the sponsor would
account for the loan as R&D expense.
Pure equity partnership arrangements designed to launch
new companies present other accounting problems. The initial
issue is: Are the partnership and sponsor really separate entities,
or are the limited partners merely investors in the sponsor? While
the legal form may indicate separate entities, the substance of
the arrangement may dictate that the sponsor and the
partnership be combined for accounting purposes. Other issues
arise when the partnership incorporates or when the partnership
and the sponsor combine. Generally, when the partnership and
the sponsor have been combined for financial accounting
purposes and a legal combination of the entities occurs, such a
combination will be treated similar to a pooling of interests. But,
again, the specific circumstances surrounding each situation
must first be evaluated.
Many of these accounting issues have not been fully
resolved by the accounting profession, and will ultimately be
addressed by interpretation of existing accounting rules and
establishment of new accounting standards. In the meantime,
those considering the formation of R&D partnerships should consult accounting professionals as to the potential accounting consequences of any contemplated arrangement.
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